Pr ot o c ol I D R -O M -0 2 -U S A  
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 1 of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7 S e pt e m b er 2 0 1 9  S G X 9 4 2  ( D U S Q U E TI D E)  
I D R - O M- 0 2 -U S A  
A PI V O T A L, D O U B L E -B LI N D, R A N D O MI Z E D, P L A C E B O -C O N T R O L L E D , 
M U L TI N A TI O N A L  S T U D Y O F S G X 9 4 2  ( D U S Q U E TI D E)  F O R T H E T R E A T M E N T O F 
O R A L M U C O SI TI S I N P A TI E N T S B EI N G  T R E A T E D WI T H C O N C O MI T A N T 
C H E M O R A DI A TI O N F O R T H E T R E A T M E N T O F S Q U A M O U S C E L L C A R CI N O M A 
O F T H E H E A D A N D N E C K   
S p o ns or:  Soli ge ni x , I nc. 
2 9 E m m o ns Dri ve 
S uite B- 1 0 
Pri ncet o n, NJ 0 8 5 4 0 
( 6 0 9) 5 3 8- 8 2 0 0 
D oc u me nt D at e : 
Ori gi n al  1 1 J a n uar y 2 0 1 7 
A me n d me nt  1 2 9 N o ve m ber 2 0 1 7  
A me n d me nt 2  2 2 J a n uar y 2 0 1 8 
A me n d me nt 3 1 7 Se pte m ber 2 0 1 9 
U S I N D N u m ber:   
Me dic al M o nit or  Ric har d Stra u be, M D 
C O N FI D E N TI A LI T Y S T A T E M E N T  
T he i nf or mati o n i n t his d oc u me nt c o ntai ns tra d e secrets a n d c o m mer cial i nf or mati o n t hat are 
pri vile ge d or c o nfi d e ntial a n d ma y n ot be discl ose d u nless s uc h discl os ure is re q uire d b y f e deral 
or state la w or re g ulati o ns . I n a n y e ve nt, p ers o ns t o w h o m t he i nf or mati o n is discl ose d m ust be 
i nf or me d t hat t he i nf or m ati o n is pri vile ge d or c o nfi de ntial a n d ma y n ot be f urt her discl ose d b y 
t he m . T hese restri cti o ns o n discl os ure will a p pl y e q uall y t o all f ut ure i nf or mati o n s u p plie d t o 
y o u, w hic h is i n dicat e d as pri vile ge d or c o nfi d e ntial.  N C T 0 3 2 3 7 3 2 5 
Pr ot o c ol I D R -O M -0 2 -U S A    
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 3 of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7 S e pt e m b er 2 0 1 9  1.  P R O T O C O L S Y N O P SI S  
N a me of S p o ns or/ C o m p a n y:  
S oli ge ni x, I nc. 
N a me of I n vesti g ati o n al Pr o d uct:  
S G X 9 4 2 ( d us q ueti de),   sterile s ol uti o n f or i ntra ve n o us (I V) i nf usi o n  
N a me of Acti ve I n gre die nt:  
D us q ueti de (researc h na me S G X 9 4),  f ull y s y nt hetic n o vel pe nta pe pti de  
Title of St u d y:  
A  Pi v otal,  D o u ble -Bli n d,  Ra n d o mize d,  Place b o -C o ntr olle d,  M ulti nati o nal  St u d y  of  S G X 9 4 2  
( D us q ueti de)  f or  t he  Treat me nt of  Oral  M uc ositis  i n  Patie nts  Bei n g  Treate d  wit h  C o nc o mita nt  
C he m ora diati o n f or t he Treat me nt of S q ua m o us Cell Carci n o ma of t he Hea d a n d N ec k  
St u d y Ce nter(s): A t otal of 5 0 -6 0 ce nters i n t he U S A a n d E U  
P ri nci p al I n vesti g at or:  
St u die d Peri o d ( ye ars):  
Esti mate d date first patie nt e nr olle d: N o ve m ber [ADDRESS_1183369] patie nt e nr olle d: Marc h 2 0 2 0 P h ase of De vel o p me nt:  
P hase 3 
O bjectives:  
P ri m ar y O bjecti ve:  
• T o assess t he efficac y of S G X [ADDRESS_1183370] b o i n decreasi n g t he d urati o n of se vere oral 
m uc ositis ( S O M; defi ne d as W orl d Healt h Or ga nizati o n [ W H O ] Gra de lesi o n ≥ 3) i n patie nts 
recei vi n g fracti o nate d ra diati o n treat me nts a n d c o nc o mita nt cis plati n c he m ot hera p y, gi ve n as 8 0- 
1 0 0 m g/ m 2 e ver y t hir d wee k, f or t he treat me nt of s q ua m o us cell carci n o ma of t he oral ca vit y or 
or o p har y n x.  
Sec o n d ar y O bjecti ves:  
T o assess t he i m pact of S G X [ADDRESS_1183371] b o o n t he f oll o wi n g  cli nicall y i m p orta nt sec o n dar y 
o bj ecti ves : 
1.  To assess t he i m pact t hat S G X 9 4 2 has o n t he Area - U n der-t he- C ur ve ( A U C) f or S O M ( W H O 
Gra de ≥ 3 ) b y ti me pl ot (se verit y - wei g hte d d urati o n) 
2.  To assess  t he i m pact t hat S G X 9 4 2 has o n t he Area - U n der-t he- C ur ve ( A U C) f or ulcerati ve oral 
m uc ositis ( U O M; defi ne d as W H O Gra de ≥ 2) b y ti me pl ot (se verit y - wei g hte d d urati o n) 
3.  To assess t he i m pact t hat S G X [ADDRESS_1183372] t hat S G X 9 4 2 has o n t he qualit y of life assess me nt usi n g t he E ur o pea n 
Or ga nizati o n f or Researc h a n d Treat me nt of Ca ncer ( E O R T C) Q ualit y of Life Q uesti o n f or 
Hea d a n d Nec k Ca ncer 4 3 q uesti o n ( Q L Q H & N 4 3) i nstr u me nt 
5.  To assess t he i m pact t hat S G X [ADDRESS_1183373] b o o n t he f oll o wi n g  a d diti o nal sec o n dar y 
o bj ecti ves : 
• To assess t he i m pact t hat S G X 9 4 2 has o n t he c u m ulati ve n u m ber of da ys of R T brea ks 
• To assess t he i m pact t hat S G X 9 4 2 has o n t he d urati o n of S O M; i n all ra n d o mize d patie nts 
recei vi n g fracti o nate d R T a n d c o nc o mita nt cis plati n c he m ot hera p y, gi ve n as 8 0 -1 0 0 m g/ m 2 
Pr ot o c ol I D R -O M -0 2 -U S A    
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 4 of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7 S e pt e m b er 2 0 1 9  e ver y t hir d wee k  (I T T p o p ulati o n)  
• To assess t he i m pact t hat S G X 9 4 2 has o n t he d urati o n of U O M 
• To assess t he i m pact t hat S G X 9 4 2 has o n t he c u m ulati ve a m o u nt of pai n re p orte d b y patie nts 
• T he d urati o n of S O M usi n g a n alter nati ve defi niti o n calc ulate d as t he n u m ber of da ys fr o m t he 
first oral e xa mi nati o n wit h W H O gra de ≥ [ADDRESS_1183374] assess me nt wit h a W H O sc ore ≥ 3 
(a n d n ot t o t he first as sess me nt wit h a W H O gra de < 3) wit h n o f urt her re p orts of a W H O gra de 
≥ 3 . 
• T he d urati o n of S O M i n t he Per- Pr ot oc ol P o p ulati o n defi ne d as patie nts recei vi n g  a c u m ulati ve 
ra diati o n d ose of at least [ADDRESS_1183375] u g sc he d ule d.  
S af et y O bj ecti ve : 
Safet y o bj ecti ves will i ncl u de t he f oll o wi n g:  
• To assess t he i m pact t hat S G X 9 4 2 has o n t he A d verse E ve nts ( A E) a n d seri o us A d verse E ve nts 
( S A E)  
• To assess t he i m pact t hat S G X 9 4 2 has o n c ha n ges i n safet y la b orat or y val ues  
• To assess t he i m pact t hat S G X 9 4 2 has o n t he Res p o nse E val uati o n Criteria i n S oli d T u m ors 
(R E CI S T ) cate g orizati o n of t he pri mar y t u m or at [ADDRESS_1183376] - C R T  
• T o assess t he i m pact of S G X 9 4 2 o n t he i nci de nce of re p orte d pres u me d bacterial i nfecti o ns 
bet wee n Baseli ne a n d 6 wee ks after c o m pleti o n of ra diati o n t hera p y ( R T) b y t otal n u m ber a n d 
b y se verit y of i nfecti o n, gra de d usi n g t he Nati o nal Ca ncer I nstit ute’s ( N CI’s) C o m m o n 
T er mi n ol o g y Criteria f or A d verse E ve nts ( C T C A E)  
• T o assess t he i m pact of S G X 9 4 2 o n 1 2 m o nt h all- ca use m or talit y  
• T o assess t he i m pact of S G X 9 4 2 o n pr o gressi o n free s ur vi val t hr o u g h 1 2 m o nt hs 
Met h o d ol o g y:  
A p pr o xi matel y 2 6 0 patie nts wit h s q ua m o us cell carci n o ma of t he oral ca vit y a n d or o p har y n x sc he d ule d 
t o recei ve a mi ni m u m t otal c u m ulati ve ra diati o n d ose of 5 5 G y fracti o nate d as 2. 0- 2. 2 G y per da y a n d 
c o nc o mita nt cis plati n c he m ot hera p y gi ve n as a d ose of 8 0 -1 0 0 m g/ m 2 ( e ver y t hir d wee k ) will be 
e nr olle d. S u bjects will be ra n d o mize d t o recei ve eit her 1. 5 m g/ k g S G X [ADDRESS_1183377] u g will be starte d wit hi n 3 da ys 
after starti n g R T  a n d c o nti n ue d t w ice a wee k ( 2 -4 cale n dar da ys a part) t hr o u g h [ADDRESS_1183378]- R T c o m pleti o n visits. O M will be e val uate d usi n g t he W H O Gra de s ys te m 
a n d perf or me d b y o bser vers trai ne d o n t hese meas ure me nts. S O M is defi ne d as a W H O Gra de of ≥ 3. 
T he d urati o n of S O M is defi ne d as t he first ti me t he patie nt has a W H O Gra de ≥ [ADDRESS_1183379] ti me t he 
patie nt has a W H O Gra de of < 3 wit h n o s u bse q ue nt rea di n gs ≥3. Patie nts will be ra n d o mize d ( 1: 1; 1. 5 
m g/ k g S G X 9 4 2: place b o) usi n g a n i nteracti ve we b res p o nse s yste m (I W R S). Ra n d o mizati o n will be 
stratifie d b y site, prese nce of pr o p h ylactic gastr ost o m y fee di n g t u be, a n d t u m or h u ma n pa pi[INVESTIGATOR_4382] o ma vir us 
( H P V) stat us.  
R o uti ne cli nical c he mistr y a n d he mat ol o g y will be o btai ne d at Scree ni n g/ Baseli ne, t he n at 3, 6, a n d [ADDRESS_1183380]- R T c o m pleti o n visit. T he sa me 
t y pe of sca n i nitiall y use d t o sta ge t he t u m or (i.e. , c o m p ute d t o m o gra p h y  [ C T ], ma g netic res o na nce 
i ma gi n g [ M RI ] or p ositr o n e missi o n t o m o gra p h y [ P E T ]) will be re peate d at 1 2 wee ks  a n d 1 2 m o nt hs 
after c o m pleti o n of t he ra diati o n t hera p y a n d c o m pare d t o t he i nitial sca n usi n g t he R E CI S T 1. 1 
criteria.  
N u m ber o f P atie nts ( pl a n ne d):  
2 6 0 patie nts ( [ADDRESS_1183381] b o treate d patie nts) will be e nr olle d.  
Pr ot o c ol I D R -O M -0 2 -U S A    
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 5 of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7 S e pt e m b er 2 0 1 9  Di a g n osis a n d M ai n Criteri a f or I ncl usi o n:  
I ncl usi o n Criteri a  
Patie nts m ust meet all  of t he f oll o wi n g criteria i n or der t o be eli gi ble f or e nr oll me nt:  
1.  Willi n g a n d a ble t o u n dersta n d a n d si g n a n i nf or me d c o nse nt 
2.  Males or fe males a ge greater t ha n or e q ual t o 1 8 years  
3.  Bi o ps y- pr o ve n s q ua m o us cell carci n o ma of t he oral ca vit y or or o p har y n x wit h o ut dista nt or ga n 
metastases  t hat has bee n e val uate d f or h u ma n pa pi[INVESTIGATOR_4382] o ma vir us ( H P V) 
4.  Sc he d ule d t o recei ve cis plati n c he m ot hera p y of 8 0- 1 0 0 m g/ m² gi ve n e ver y t hir d wee k 
5.  Sc he d ule d t o recei ve a c o nti n u o us c o urse of c o n ve nti o nal e xter nal bea m irra diati o n de li vere d 
b y i nte nsit y - m o d ulate d ra di ot hera p y (I M R T) as si n gle dail y fracti o ns of 2. [ADDRESS_1183382] 2 oral sites (retr o m olar tri g o ne, b uc cal 
m uc osa, fl o or of m o ut h, t o n g ue, or s oft palate), wit h eac h site rec ei vi n g ≥ 5 5 G y  
7.  All w o me n of c hil d beari n g p ote ntial ( W O C B P) a n d males wit h fe male part ners w h o are 
W O C B P m ust a gree t o t he use of effecti ve c o ntrace pti o n d uri n g t he trial.  
• W o me n are c o nsi dere d t o be W O C B P f oll o wi n g me narc he a n d u ntil bec o mi n g p ost- 
me n o pa usal u nless per ma ne ntl y sterile ( h ysterect o m y, bilateral sal pi n gect o m y a n d bilateral 
o o p h orect o m y). A p ost me n o pa usal state is defi ne d as n o me nses f or [ADDRESS_1183383] u g a d mi nistrati o n.  
• Acce pta ble c o ntrace pti ve met h o ds f or W O C B P are t h ose t hat ac hie ve a fail ure rate of less 
t ha n 1 % per year a n d i ncl u de:  
o C o m bi ne d (estr o ge n a n d pr o gest o ge n c o ntai ni n g) h or m o nal c o ntrace pti o n 
ass ociate d wit h i n hi biti o n of o v ulati o n:  
  Oral  
 I ntra va gi nal  
 Tra ns der mal  
o Pr o gest o ge n - o nl y h or m o nal c o ntrace pti o n ass ociate d wit h i n hi biti o n of 
o v ulati o n:  
 Oral  
 I nj ecta ble  
 I m pla nta ble  
o I ntra uteri ne de vice (I U D)  
o I ntra uteri ne h or m o ne- releasi n g s yste m ( I U S)  
o Bilateral t u bal occl usi o n  
o Vasect o mize d  part ner  
o Se x ual a bsti ne nce defi ne d as refrai ni n g fr o m heter ose x ual i nterc o urse d uri n g 
t he e ntire peri o d of ris k ass ociate d wit h t he st u d y treat me nts 
• Male s u bjects s h o ul d use c o n d o ms d uri n g treat me nt a n d f or [ADDRESS_1183384] u g a d mi nistrati o n peri o d. 
E xcl usi o n Criteri a  
Patie nts wit h a n y of t he f oll o wi n g criteria are N O T  eli gi ble f or e nr oll me nt:  
1.  C urre nt m uc ositis 
Pr ot o c ol I D R -O M -0 2 -U S A    
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 7 of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7 S e pt e m b er 2 0 1 9  Criteri a f or Ev al u ati o n:  
Effic ac y:   
Efficac y will be deter mi ne d i n patie nts w h o ha ve recei ve d e n o u g h ra diati o n e x p os ure t o p ut t he m at 
si g nifica nt ris k of de vel o pi n g S O M ( defi ne d as a c u m ulati ve ra diati o n d ose of at least 5 5 G y).  
Pri m ary E n d p oi nt: 
T he pri mar y efficac y o utc o me f or t his st u d y is t he d urati o n of S O M, defi ne d as t he n u m ber of da ys 
fr o m t he first oral e xa mi nati o n wit h a W H O Gra de assess me nt of ≥ [ADDRESS_1183385] ti me t he patie nt has 
a W H O Gra de of < 3 wit h n o s u bse q ue nt rea di n gs ≥ 3 .  
Sec o n d ary e n d p oi nts will be a n alyze d i n hier arc hic al or der:  
1.  The Area - U n der-t he- C ur ve ( A U C) f or S O M ( W H O Gra de ≥ 3) b y ti me pl ot (se verit y - wei g hte d 
d urati o n) 
2.  The Area - U n der-t he- C ur ve ( A U C) f or ulcerati ve oral m uc ositis ( U O M; defi ne d as W H O 
Gra de ≥ 2) b y ti me pl ot (se verit y - wei g hte d d urati o n) 
3.  The i nci de nce of S O M  
4.  The q ualit y of life assess me nt usi n g t he E ur o pea n Or ga nizati o n f or Researc h a n d Treat me nt of 
Ca ncer ( E O R T C) Q ualit y of Life Q uesti o n naire 3 0 q uesti o n m o d ule ( E O R T C Q L Q- C 3 0 
( versi o n 3)) a n d t he E O R T C Hea d a n d Nec k Ca ncer latest 4 3 q uesti o n m o d ule ( Q L Q- H & N 4 3) 
i nstr u me nt 
5.  The a m o u nt of o pi [INVESTIGATOR_851178] d  
 
T he f oll o wi n g sec o n d ary e n d p oi nts will als o be ex a mi ne d:  
• The c u m ulati ve n u m ber of da ys of ra diati o n treat me nt brea ks 
• T he d urati o n of S O M i n all ra n d o mize d patie nts recei vi n g fracti o nate d R T a n d c o nc o mita nt 
cis plati n c he m ot hera p y, gi ve n as 8 0- 1 0 0 m g/ m 2 e ver y t hir d wee k (I T T p o p ulati o n) 
• T he d urati o n of U O M 
• T he c u m ulati ve a m o u nt of pai n re p orte d b y patie nts 
• T he d urati o n of S O M usi n g a n alter nati ve defi niti o n calc ulate d as t he n u m ber of da ys fr o m t he 
first oral e xa mi nati o n wit h W H O gra de ≥ [ADDRESS_1183386] assess me nt wit h a W H O sc ore ≥ 3 
(a n d n ot t o t he first assess me nt wit h a W H O gra de < 3) wit h n o f urt her re p orts of a W H O gra de 
≥ 3.  
• T he d urati o n of S O M i n t he Per -Pr ot oc ol P o p ulati o n defi ne d as patie nts recei vi n g a c u m ulati ve 
ra diati o n d ose of at least [ADDRESS_1183387] u g.  
S af et y:  
• T he i nci de nce, t y pe, a n d b o d y s yste m cate g orizati o n of A Es  
• The i nci de nce, t y pe, a n d b o d y s yste m cate g orizati o n of S A Es  
• T he c ha n ges fr o m B aseli ne f or he mat ol o g y para meters, cli nical c he mistr y para meters, a n d vital 
si g ns  
• T u m or stat us at  1 2 wee ks  a n d 1 2 m o nt hs f oll o wi n g c o m pleti o n of R T cate g orize d usi n g t he 
R E CI S T criteria  
• T he i nci de nce a n d se verit y of re p orte d i nfecti o ns assesse d b y C T C A E gra di n g  
• T he [ADDRESS_1183388]- R T s ur vi val  
Pr ot o c ol I D R -O M -0 2 -U S A    
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 9 of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7 S e pt e m b er 2 0 1 9  2.  T A B L E O F C O N T E N T S, LI S T O F T A B L E S, A N D LI S T O F 
FI G U R E S  
2. 1.  T a ble of C o nte nts 
1.  P R O T O C O L S Y N O P SI S  ................................................................................................ ..... 3  
2.  T A B L E O F C O N T E N T S, L I S T O F T A B L E S, A N D L I S T O F FI G U R E S  ..................... 9  
2. 1.  T A B L E O F CO N T E N T S  ................................................................................................ ....... 9  
2. 2.  L I S T O F TA B L E S  ............................................................................................................. 1 2  
2. 3.  L I S T O F FI G U R E S  ............................................................................................................ 1 2  
2. 4.  A P P E N DI C E S  ................................................................................................................... 1 3  
3.  LI S T O F A B B R E VI A TI O N S A N D D E FI NI TI O N S O F  T E R M S  ................................. 1 4  
4.  I N T R O D U C TI O N ............................................................................................................... 1 6  
4. 1. S G X 9 4 2  ( D U S Q U E TI D E ) ................................................................................................ [ADDRESS_1183389] A N : DE S C RI P TI O N  ...................................................... 3 0  
6. 2.  S P E CI FI C AS S E S S M E N T S  ................................................................................................. 3 2  
6. 2. 1  Or al M uc ositis ( O M) Gr a di n g .................................................................................. [ADDRESS_1183390] or y  ................................................................................................ 3 5  
6. 2. 6. 2. P h ysical E x a mi nati o n ........................................................................................ 3 5  
6. 2. 6. 3. Q ualit y of Lif e Q uesti o n naire  ........................................................................... 3 5  
6. 2. 6. 4. Vital Si g ns  ......................................................................................................... 3 5  
6. 2. 6. 5.  Hei g ht a n d B o d y M ass I n de x ( B MI) ................................................................ 3 6  
Pr ot o c ol I D R -O M -0 2 -U S A    
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 1 1  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183391]- R T Cli nic Visit  .................. 5 2  
1 1. 1. 7  Pr o gressi o n -free S urviv al  ..................................................................................... 5 2  
1 1. 2.  S A F E T Y PA R A M E T E R S  .................................................................................................... 5 3  
1 1. 2. 1  A dverse E x perie nce ( A E)  ...................................................................................... 5 3  
1 1. 2. 2  Seri o us A dverse E x perie nce ( S A E)  ....................................................................... [ADDRESS_1183392] U G  .................................................................................... 5 3  
1 1. 4.  S E V E RI T Y O F AD V E R S E EV E N T  ...................................................................................... 5 4  
1 1. 5.  R E P O R TI N G AD V E R S E EV E N T S  ....................................................................................... 5 4  
1 1. 5. 1  A dverse E ve nts  ...................................................................................................... 5 4  
1 1. 5. 2  Seri o us A dverse E ve nts  ......................................................................................... 5 4  
1 1. 6.  D A T A MO NI T O RI N G CO M MI T T E E  ................................................................................... 5 5  
1 2.  S T A TI S TI C S  ....................................................................................................................... 5 7  
1 2. 1.  O V E R VI E W  ..................................................................................................................... 5 7  
  
1 2. 3.  F I N A L AN A L Y SI S  ............................................................................................................ 5 8  
1 2. 4.  S A M P L E SI Z E CA L C U L A TI O N  .......................................................................................... 5 8  
1 2. 5.  S E L E C TI O N O F PRI M A R Y AN A L Y SI S PO P U L A TI O N  .......................................................... 5 8  
1 2. 6.  D I R E C T AC C E S S T O SO U R C E DA T A / D O C U M E N T S  ........................................................... [ADDRESS_1183393] u dy Ev al u ati o n ............................................................................................ 5 9  
1 2. 6. 3  Site I niti ati o n Visit  ................................................................................................ 5 9  
1 2. 6. 4  M o nit ori n g Visits  .................................................................................................. 5 9  
1 2. 6. 5  Cl ose- o ut Visit  ....................................................................................................... 6 0  
1 2. 7.  A U DI T S A N D IN S P E C TI O N S  ............................................................................................. 6 0  
1 3.  I N S TI T U TI O N A L R E VI E W  B O A R D (I R B)/ E T HI C A L C O M MI T T E E ( E C)  ........... [ADDRESS_1183394] U D Y  ................................................................................ 6 3  
1 5. 3.  W RI T T E N IN F O R M E D CO N S E N T  ...................................................................................... 6 3  
1 5. 4.  S U BJ E C T DA T A PR O T E C TI O N  .......................................................................................... 6 3  
1 5. 5.  F I N A N CI A L DI S C L O S U R E  ................................................................................................ 6 3  
Pr ot o c ol I D R -O M -0 2 -U S A    
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 1 4  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7 S e pt e m b er 2 0 1 9  3.  LI S T O F A B B R E VI A TI O N S A N D D E FI NI TI O N S O F  T E R M S 
T a ble 2: A b bre vi ati o ns a n d s peci alist ter ms  
A b bre vi ati o n or s peci alist ter m  E x pl a n ati o n 
A E  A d verse e ve nt  
A L T  Ala ni ne a mi n otra nsferase  
A S T  As partate a mi n otra nsferase  
A U C  Area u n der t he c ur ve  
B A L  Br o nc h oal ve olar la va ge  
B MI  B o d y mass i n de x  
B U N  Bl o o d urea nitr o ge n  
C F R  C o de of fe deral re g ulati o ns 
C ma x  Ma xi m u m c o nce ntrati o n 
C N S  Ce ntral ner v o us s yste m  
C O [ADDRESS_1183395] u g A d mi nistrati o n  
G C P  G o o d cli nical practices 
G L P  G o o d la b orat or y practices  
H E D  H u ma n e q ui vale nt d ose  
H C G  H u ma n c h ori o nic g o na d otr o pi n 
H P V  H u ma n pa pi[INVESTIGATOR_4382] o ma vir us 
I B  I n vesti gat or’s br oc h ure  
I C F  I nf or me d c o nse nt f or m  
Pr ot o c ol I D R -O M -0 2 -U S A    
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 1 5  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183396] le vel  
O M  Oral m uc ositis  
P E G  Perc uta ne o us e n d osc o pic gastr o n o m y  
P E T  P ositr o n e missi o n t o m o gra p h y  
P D  P har mac o d y na mics  
PI  [INVESTIGATOR_1307] i n vesti gat or  
P K  P har mac o ki netic  
P P  Per pr ot oc ol  
P R  Partial res p o nse  
R B C  Re d bl o o d cell 
R T  Ra diati o n t hera p y  
S A E  Seri o us a d verse e ve nt  
S D  Sta ble disease  
S O M  Se vere oral m uc ositis  
Tma x  Ti me at w hic h t he ma xi m u m bl o o d c o nce ntrati o n was ac hie ve d  
U O M  Ulcerati ve oral m uc ositis  
W B C  W hite bl o o d cell  
W H O  W orl d Healt h Or ga nizati o n 
Pr ot o c ol I D R -O M -0 2 -U S A    
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 1 6  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7 S e pt e m b er 2 0 1 9  4.  I N T R O D U C TI O N  
T his secti o n  c o ntai ns a brief descri pti o n of t he rati o nale a n d a v aila ble i nf or mati o n c o ncer ni n g t he 
c he mistr y, n o n-cli nical p har mac ol o g y a n d t o xic ol o g y, p har mac o ki netics ( P K) , 
p har mac o d y n a mics ( P D), a n d pre vi o us cli nical e x perie nce wit h S G X 9 4 2 . Please r efer t o t he 
I n v esti gat or's Br oc h ur e (I B) f or a d diti o nal details a n d i nf or mati o n. 
4. 1.  S G X 9 4 2 ( D us q ueti de)  
D us q ueti de is a fi ve a mi n o -aci d pe pti de t hat bi n ds t o t he i ntracell ular p 6 2 pr otei n [ 1] res ulti n g i n 
m o d ulati o n of t he i n nat e i m m u n e res p o nse t o b ot h i nfecti o n a n d  tiss ue da m a ge b y re d u ci n g  
i n d ucti o n of i nfla m mati o n a n d i ncreasi n g m acr o p ha ge acti vati o n/ recr uit me nt, res ulti n g  i n  
i ncreas e d  bact erial cleara nce a n d tiss ue heali n g  [ 2 - 4]. T he dr u g is f or m ulat e d as  a n   a q ue o us, 
sterile  s ol uti o n  f or  i njecti o n  c o ntai ni n g 6 0 m g/ m L of d us q ueti de . T he  f or m ulati o n  c o ntai ns  n o 
preser vati ves  a n d   n o e xci pie nts . T he dr u g will be gi ve n at a d ose of 1. 5 m g/ k g. Dr u g will be 
dil ute d i nt o a n i nf use d v ol u me of [ADDRESS_1183397] u dies were c o n d ucte d i n 
mice a n d n o n- h u ma n pri mates ( N H Ps). Tr a nsie nt, hi g h -d ose ac ute t o xicit y was o bser v e d  i n b ot h 
m o use a n d N H P . Res ol uti o n occ urr e d wit hi n mi n utes i n s ur vi vi n g a ni mals wit h n o l o n g- ter m 
se q uelae.  
Pil ot t o xic ol o g y st u dies i n dicate d t hat t he ma xi m u m t olerate d d ose ( M T D) of a si n gl e 
a d mi nistrati o n of d us q ueti de, a d mi nistere d as a n I V i njecti o n o ver 3 0 t o 6 0 sec o n ds, is 8 8 m g/ k g 
i n mice. I n N H P, mil d cli nic al si g ns (i.e., s h all o w/la b ore d r es pi[INVESTIGATOR_1313] o n, decrease d acti vit y, 
partiall y cl ose d e yes , a n d m uscle t witc hes) were n ote d i n 1 or b ot h a ni mals after a d mi nistrati o n 
of 9 0 ( 1 a ni mal), 1 8 0 ( b ot h a ni mals), a n d 2 2 0 ( 1 a ni mal) m g/ k g d us q ueti de d uri n g a n d s h ortl y 
after d osi n g. T hes e res ol ve d wit hi n a fe w mi n utes wit h o ut detecta ble r esi d ual eff ects.  
T he safet y of m ulti ple dail y i njecti o ns of d us q ueti de has als o bee n e val u ate d i n G L P st u dies i n 
mice a n d N H Ps. I n mice, d oses of 2 0, 6 0, or 9 0 m g/ k g/ da y w ere gi ve n I V f or 1 4 da ys. Deat hs 
were o bs er ve d at t he hi g h d ose, prece de d mai nl y b y la b or e d r es pi[INVESTIGATOR_1313] o n a n d rec u m be n c y. 
Let h alit y w as als o o bser v e d i n 1 a ni mal gi v e n 6 0 m g/ k g b ut n o ot her a ni m als e x hi bite d cli nical 
si g ns at t his d ose. N o test article -r elate d m ortalit y or cli nical si g ns w er e o bser ve d at 2 0 m g/ k g. I n 
s ur vi v ors of all gr o u ps, t here w as n o e vi de n ce of t o xicit y i n a n y or ga n or a b n or mal bi oc he mistr y 
or he mat ol o g y. N o A E s were o bs er ve d at 2 0 m g/ k g a d mi nister e d dail y f or 1 4 da ys. 
D us q ueti de at 2 0, 8 0, or 1 6 0 m g/ k g/ da y was gi ve n I V t o c y n o m ol g us m o n ke ys f or 1 4 da ys. 
Tra nsie nt decrease d acti vit y a n d partiall y cl ose d e yes c o nti n ue d t o be o bser ve d d uri n g a n d 
s h ortl y aft er d osi n g at 1 6 0 m g/ k g f or t he first [ADDRESS_1183398] a ni mals, t he n s p ora dicall y 
t hr o u g h o ut t he r e mai ni n g d osi n g peri o d. I n all cas es, t hese cli nical si g ns res ol ve d wit hi n a fe w 
mi n utes. N o A E s were o bser ve d o n a n y ot h er meas ure d para meter or micr osc o pi[INVESTIGATOR_1306] y i n a n y 
tiss ue. T he a d mi nistrati o n of d us q ueti de at d oses of 2 0 a n d 8 0 m g/ k g/ da y di d n ot res ult i n a n y 
Pr ot o c ol I D R -O M -0 2 -U S A    
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 2 1  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7 S e pt e m b er 2 0 1 9  T a ble 3: Re p orte d I nf ecti o ns  
Tre at me nt Gr o u p  Pl ace b o  
n = 3 8  1. 5 m g/ k g 
n = 3 6  6. 0 m g/ k g 
n = 1 9  
All I nfecti o ns: n 
  ( %)  
  p-v al ue c o m p are d t o pl ace b o  2 9 
( 7 6 %) 
— 2 3 
( 6 4 %) 
0. 3 1 1  8 
( 4 2 %) 
0. 0 1 8  
N o n -f u n g al I nfecti o n: n  
  ( %)  
   p-v al ue c o m p are d t o pl ace b o  1 7 
( 4 5 %) 
— 1 0 
( 2 8 %) 
0. 1 5 3  4 
( 2 1 %) 
0. 1 4 4  
Seri o us I nfecti o n: n  
   ( %)  
   p-v al ue c o m p are d t o pl ace b o  8 
( 2 1 %) 
— 7 
( 1 9 %) 
> 0. 9 9 9  3 
( 1 6 %) 
0. 7 3 5  
 
I n t he mI T T p o p ulati o n, t he n u m ber of p atie nts wit h R E CI S T e val uati o ns cate g orize d as 
c o m plete res p o nses t o t h era p y w as i ncrease d fr o m  1 5/ 3 8 ( 3 9 %) i n t he place b o gr o u p t o 1 7/ 3 6 
( 4 7 %) i n t he 1. 5 m g/ k g S G X 9 4 2 d ose gr o u p, a 2 1 % i ncrease. Disre gar di n g t h ose patie nts wit h 
missi n g or n ot assesse d t u m or stat us, t his i ncrease was 3 4 % i n  t he S G X 9 4 2 1. 5 m g/ k g gr o u p. 
T his is c o nsiste nt wit h precli nical st u dies s h o wi n g i m pr o ve d s ur vi val a n d d ecrease d t u m or 
v ol u me size ( 3). O ver t he l o n ger t er m, t he o verall r es ol uti o n rate i n t he place b o p o p ulati o n was 
hi g h, ma ki n g f urt h er i m pr o ve me nt diffic ult t o de m o nstrate.  H o we v er, S G X 9 4 2 defi nitel y di d n ot 
decrease t he eff ecti ve ness of C R T t hera p y  ( Ta bl e 4). Si milarl y, t he o ver all 1 -year s ur vi val rate 
was si milar bet wee n gr o u ps a n d m ore f a v ora ble f or t he S G X 9 4 2 treat e d gr o u ps ( Ta ble 5).  
T a ble 4: I nci de nce of T u m or C o m plete Res p o nse as a F u ncti o n of Tre at me nt Gr o u p a n d 
Ti me p oi nt  ( S af et y P o p ul ati o n) * 
R E CI S T Res p o nse  Pl ace b o  
n = 4 1  1. 5 m g/ k g  
n = 4 2  3. 0 m g/ k g  
n = 3  6. 0 m g/ k g  
n = 2 3  
1-m o nt h f oll o w -u p  1 5/ 3 2 ( 4 7 %)  1 7/ 2 7 ( 6 3 %)  1/ 3 ( 3 3 %)  4/ 1 6 ( 2 5 %)  
3-m o nt h f oll o w -u p  1 7/ 2 7 ( 6 3 %)  1 8/ 2 7 ( 6 7 %)  1/ 1 ( 1 0 0 %)  9/ 1 7 ( 5 3 %)  
6-m o nt h f oll o w -u p  1 9/ 2 4 ( 7 9 %)  1 9/ 2 8 ( 6 8 %)  1/ 1 ( 1 0 0 %)  1 0/ 1 4 ( 7 1 %)  
9-m o nt h f oll o w -u p  6/ 8 ( 7 5 %)  1 4/ 1 6 ( 8 8 %)  2/ 2/ ( 1 0 0 %)  1/ 3 ( 3 3 %)  
1 2 -m o nt h f oll o w -u p  2 2/ 2 3 ( 9 6 %)  1 9/ 2 3 ( 8 3 %)  1/ 2 ( 5 0 %)  1 0/ 1 2 ( 8 3 %)  
L O C F * * t hr o u g h 1 2 -m o nt h f oll o w -u p  2 6/ 3 5 ( 7 4 %)  2 8/ 3 5 ( 8 0 %)  1/ 3 ( 3 3 %)  1 3/ 2 2 ( 5 9 %)  
* P erce nta ge calc ulati o n e xcl u des missi n g/ n ot assesse d e val uati o ns  
* * Last O bser vati o n Carrie d F or war d  
 
T a ble 5: M ort alit y (I T T P o p ul ati o n 1) 
M ort alit y  Pl ace b o  
n = 4 3  1. 5 m g/ k g  
n = 4 1  3. 0 m g/ k g  
n = 3  6. 0 m g/ k g  
n = 2 4  
T hr o u g h 1 2 -m o nt h f oll o w -u p  9 ( 2 1 %)  3 ( 7 %)  0 4 ( 1 7 %)  
[ADDRESS_1183399] u g d ose  
Pr ot o c ol I D R -O M -0 2 -U S A    
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 2 8  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183400] b o i n decreasi n g t he d urati o n of S O M  
(defi ne d as W H O Gra d e lesi o n ≥ 3) i n patie nts recei vi n g fra cti o nate d ra diati o n treat me nts  a n d 
c o nc o mita nt cis plati n c he m ot hera p y , gi ve n as 8 0- 1 0 0 m g/ m [ADDRESS_1183401] b o o n t he f oll o wi n g cli nicall y i m p orta nt 
sec o n dar y o bj ecti ves : 
1.  T o assess t he i m pact t hat S G X 9 4 2 has o n t he Area- U n der-t he- C ur v e ( A U C) f or S O M 
( W H O Gra de ≥ 3 ) b y ti me pl ot (se verit y -w ei g hte d d urati o n) 
2.  T o assess t he i m pact t hat S G X 9 4 2 has o n t he Area- U n der-t he- C ur v e ( A U C) f or 
ulcerati ve oral m uc ositis ( U O M; defi ne d as W H O Gra de ≥ 2) b y ti me pl ot (se verit y -
wei g ht e d d urati o n) 
3.  T o assess t he i m pact t hat S G X [ADDRESS_1183402] t hat S G X 9 4 2 has o n t he q ualit y of life assess me nt usi n g t he E O R T C 
Q L Q - C 3 0 ( versi o n 3) a n d Q L Q - H & N [ADDRESS_1183403] b o o n t he f oll o wi n g a d diti o nal sec o n dar y 
o bjecti ves : 
• T o assess t he i m pact t hat S G X 9 4 2 has o n t he c u m ulati ve n u m ber of da ys of R T brea ks 
• T o assess t he i m pact t hat S G X 9 4 2 has o n t he d urati o n of S O M; i n all ra n d o mize d 
patie nts recei vi n g fracti o nate d R T a n d c o n c o mita nt cis plati n  c he m ot hera p y,  gi ve n as 8 0- 
1 0 0 m g/ m 2 (I T T p o p ulati o n) 
• T o assess t he i m pact t hat S G X 9 4 2 has o n t he d urati o n of U O M 
• T o assess t he i m pact t hat S G X 9 4 2 has o n t he c u m ulati ve a m o u nt of pai n re p orte d b y 
patie nts  
• T he d urati o n of S O M usi n g a n alter nati ve d efi niti o n calc ulate d as t he n u m ber of da ys 
fr o m t he first oral e x a mi nati o n wit h W H O gra d e ≥ [ADDRESS_1183404] ass ess me nt wit h a 
W H O sc ore ≥ 3 (a n d n ot t o t he first assess me nt wit h a W H O gra de < 3) wit h n o f urt her 
re p orts of a W H O gra de ≥ 3  
• T he d urati o n of S O M i n t he P er - Pr ot oc ol P o p ulati o n defi ne d as p atie nts recei vi n g a 
c u m ulati ve ra diati o n d os e of at least [ADDRESS_1183405] u g t wi ce per wee k d uri n g a n d f or 
2 wee ks after r a diati o n t hera p y  
Pr ot o c ol I D R -O M -0 2 -U S A    
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 2 9  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7 S e pt e m b er 2 0 1 9  5. 3.  S afet y O bjecti ve s 
Safet y o bj ecti ves will i ncl u de t he f oll o wi n g:  
• To assess t he i m pact t hat S G X 9 4 2 has o n t he A d v erse E ve nts ( A E) a n d seri o us A d verse 
E ve nts ( S A E)  
• To assess t he i m pact t hat S G X 9 4 2 has o n c ha n ges i n safet y la b orat or y val u es  
• T o assess t he i m pact t hat S G X 9 4 2 has o n t he Res p o nse E val uati o n Criteria i n S oli d 
T u m ors ( R E CI S T ) cate g orizati o n of t he pri mar y t u m or at 1 2 wee ks a n d 1 2 m o nt hs C R T  
• T o assess t he i m pact of S G X 9 4 2 o n t he i nci de nce of re p orte d pres u me d b acterial 
i nfecti o ns bet wee n Baseli ne a n d 6 wee ks after c o m pleti o n of ra diati o n t hera p y ( R T) b y 
t otal n u m ber a n d b y se verit y of i nf ecti o n, gra d e d usi n g t he N ati o nal Ca ncer I nstit ute’s 
( N CI’s) C o m m o n Ter mi n ol o g y Criteria f or A d verse E ve nts ( C T C A E) 
• T o assess t he i m pact of S G X 9 4 2 o n 1 2 m o nt h all- ca use m ortalit y  
• T o assess t he i m pact of S G X 9 4 2 o n pr o gressi o n fr ee s ur vi val t hr o u g h 1 2 m o nt hs 
Pr ot o c ol I D R -O M -0 2 -U S A    
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 3 0  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183406] a n: Descri pti o n  
A p pr o xi matel y [ADDRESS_1183407] b o i n treat i n g t he 
d urati o n of S O M  i n patie nts recei vi n g C R T  f or t he treat me nt of hea d a n d n ec k ca n ce r. Patie nts 
will be ra n d o mize d i nt o o ne of t w o gr o u ps ( 1. 5 m g/ k g S G X 9 4 2: Place b o) at a 1: [ADDRESS_1183408] u g ( 1. 5 m g/ k g S G X [ADDRESS_1183409] b o) wit hi n [ADDRESS_1183410] 
da y t h at a W H O Gr a de of < 3 is rec or de d wit h n o s u bse q ue nt assess me nts ≥ [ADDRESS_1183411] u d y visit da ys will be e v er y t hir d da y ( ± 1 da y) . O n 
st u d y visit da ys, p atie nts will recei ve t he 4- mi n ute  i nf usi o n of st u d y dr u g. St u d y dr u g will n ot be 
gi ve n o n t he s a me da y as c he m ot hera p y . St u d y dr u g ca n be gi ve n at a n y ti me d uri n g t he visit 
da y, b ut m ust occ ur o n t h e sa me cale n dar da y t hat is t he st u d y visit da y. T h e st u d y visit cale n d ar 
e xte n ds t o [ADDRESS_1183412] me nt (as descri be d 
bel o w) if t he treat me nt c o urse is s h orter or if treat me nt brea ks pr ol o n g t he C R T f or m ore t ha n 7 
wee ks.  
 
Pr ot o c ol I D R -O M -0 2 -U S A      
 
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 3 1  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7 S e pt e m b er 2 0 1 9  T a ble 7: Sc he d ule of E ve nts b y Wee k  
St u d y w ee k  Scree n  B ase [ADDRESS_1183413] -R T =  ti me fr o m t h e last ra diati o n t h era p y treat me nt  
2 Baseli n e i nf or mati o n n ee ds t o be o btai n e d pri or t o ( 0 t o 9 6 h o urs b ef ore) t h e first d ose of 
st u d y dr u g  
3 w = wee ks  
4 O nl y t o b e d o n e if W H O sc ore is ≥ [ADDRESS_1183414] -R T visit  
5 m = m o nt hs; p atie nt c o ntact (cli nic visit, tele p h o n e, or e mail) re q uire d m o nt hl y t hr o u g h 
t h e 1 2 -m o nt h cli nic visit  
6 Ti mi n g of ra diati o n a n d c h e m ot h era p y at discreti o n of pri mar y care p h ysicia ns  
7 W H O O M = oral m u c ositis gra di n g wit h W H O Oral M u c ositis Gra di n g s yste m  
8 Vital si g ns t o  i n cl u d e te m p erat ure, wei g ht, p ulse, res pi[INVESTIGATOR_1313] o ns, a n d seate d bl o o d press ure; 
Hei g ht will b e o btai n e d at Baseli ne o nl y  
9 Safet y la bs = h e mat ol o g y a n d cli nical c h e mistr y p a n els  1 0 Sca n = o btai n i nitial sta gi n g C T/ P E T/ M RI sca ns (scree ni n g sca n m ust b e wit hi n  6 wee ks 
pri or t o Baseli n e)  
[ADDRESS_1183415] re q uire d if Baseli n e sa m ple > [ADDRESS_1183416] - R T  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 3 2  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  It is ass u me d t hat p atie nts will recei ve 7 w ee ks of R T . I n pr actice, s o me patie nts will ha ve a 
s h orter c o urs e (l o wer pla n ne d ra diati o n d ose) or st o p treat me nt earl y. Si milarl y, p atie nts wit h R T 
brea ks w h o c o m plete [ADDRESS_1183417] u g 
will be c o nti n ue d f or t he 2 wee ks f oll o wi n g ( Wee ks 7 a n d 8) a n d t he [ADDRESS_1183418] u g will c o nti n ue f or 2 wee ks ( Wee ks 9 a n d 1 0) a n d t he [ADDRESS_1183419]- ra diati o n sca n will b e o btai ne d at Wee k 2 0. 
6. 2.  S pecific Assess me nts  
6. 2. 1  Or al M uc ositis ( O M) Gr a di n g  
O M will be e val uate d b y pers o n nel trai ne d i n t he use of t he W H O Or al M uc ositis Gra di n g 
s yste m  w hic h  i ncl u d es b ot h p h ysical a n d f u ncti o n al i nf or mati o n. T his gr a di n g s yste m is wi del y 
utilize d i n O M cli nical researc h tri als i ncl u di n g t h e P hase 2 trial a n d is s h o w n i n  Ta ble 8. 
T a ble 8: W H O Or al M uc ositis Gr a di n g S yste m  
Sc or e Fi n di n gs  
0 N o fi n di n gs O R  
Pai n or er yt he ma ( n ot b ot h)  
1 Pai n a n d er yt he ma A N D  
N o ulcer  
2 Ulcer a n d/ or pse u d o me m bra ne, A N D  
A ble t o eat s oli d f o o d A N D 
A ble t o dri n k  
3 Ulcer a n d/ or pse u d o me m bra ne, A N D  
N ot a ble t o eat s oli d f o o d A N D 
A ble t o dri n k  
4 Ulcer a n d/ or pse u d o me m bra ne, A N D  
N ot a ble t o eat s oli d f o o d A N D 
N ot a ble t o dri n k  
O nl y me dical pers o n n el at t he site w h o ha ve u n d er g o n e trai ni n g a n d certifi cati o n i n usi n g t he 
W H O Gra di n g s yst e m will perf or m t he O M ass ess me nts.  
6. 2. [ADDRESS_1183420]- R T will be c o m par e d t o t he Scr ee ni n g r es ults usi n g t he R E CI S T 1. 1 s yste m. T he 
e val uati o n criteri a f or t he tar get lesi o n (t he pri mar y hea d a n d n ec k carci n o ma) ar e s h o w n i n 
Ta ble 9; t he criteria f or n o n -tar get lesi o ns ar e  s h o w n i n Ta ble 1 0 ; a n d t he criteria f or o v erall 
cate g orizati o n of t he t u m or stat us are  s h o w n i n T a ble [ADDRESS_1183421]  R T treat me nt.  
  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 3 3  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  T a ble 9: R E CI S T E v al u ati o n of t he T ar get Lesi o n 
T ar get Lesi o n Res p o nse  Me as ure me nt  
C o m plet e Res p o nse ( C R)  All tar get lesi o ns g o ne  
Partial Res p o nse ( P R)  > 3 0 % decrease fr o m baseli ne  
Pr o gressi ve Disease  > 2 0 % i ncrease fr o m s mallest s u m of l o n gest dia meter rec or de d 
si nce treat me nt starte d ( best res p o nse)  
Sta ble Disease ( S D)  Neit her Pr o gressi ve Disease  n or P artial Res p o nse 
 
T a ble 1 0: R E CI S T E v al u ati o n of t he N o n- t ar get Lesi o n  
T ar get Lesi o n Res p o nse  Me as ure me nt  
C o m plete Res p o nse ( C R)  All n o n- tar get lesi o ns g o ne  
T u m or mar kers g o ne 
Sta ble Disease ( S D)  Persiste nce of ≥ 1 n o n -tar get lesi o n  
T u m or mar ker le vel ele vate d  
Pr o gressi ve Disease  E nlar ge me nt of n o n -tar get lesi o ns  
 
T a ble 1 1 : O ver all R E CI S T Res p o nse  
T ar get Lesi o ns  N o n -t ar get Lesi o ns Ne w Lesi o ns  O ver all Res p o nse  
C R  C R  N o  C o m plete Res p o nse  
C R  S D  N o  Partial Res p o nse  
P R  N o n - P r o gressi ve 
Disease  N o  Partial Res p o nse  
S D  N o n - P r o gressi ve 
Disease  N o  Sta ble Disease  
Pr o gressi ve Disease  A n y  Yes or N o  Pr o gressi ve Disease  
A n y  Pr o gressi ve Disease  Yes or N o  Pr o gressi ve Disease  
A n y  A n y  Yes  Pr o gressi ve Disease  
 
6. 2. [ADDRESS_1183422]- R T visit . A n y i de ntifie d 
i nfecti o n will be cate g orize d as pres u me d  f u n gal, pres u me d viral, or pres u me d bacteri al . T he 
se verit y of eac h r e p orte d i nfecti o n will be gra d e d 1 t o 5 usi n g t he C T C A E.  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 3 4  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183423] u d y staff will als o re vie w wit h t he patie nt 
t heir c urr e nt prescri pti o ns f or pai n me dicati o n ( o pi [INVESTIGATOR_27968]) wit h s pecial car e ta ke n t o re vie w t he as 
nee de d  me di cati o ns t he p atie nts ha ve bee n  gi ve n as well as t he fr e q ue nc y  wit h w hic h t he y are 
ta ki n g t he m. D etails f or all of t he a b o ve will be r ec or de d  i n t he e C R F .  
I n a d diti o n, site staff will re vie w t he st u d y -s pecifi c or al h y gie ne r e q uire me nts wit h t he patie nt o n 
a wee kl y b asis.  
6. 2. [ADDRESS_1183424]  
Bl o o d sa m ples will be o btai ne d at t he Scree ni n g, Baseli ne  (if Baseli ne > 7 d a ys  fr o m Scree ni n g) , 
a n d [ADDRESS_1183425]  ( h u ma n c h ori o nic g o na d otr o pi n [ H C G])  
f or all w o me n  w h o are of c hil d beari n g p ote ntial.  
6. 2. 5. 2.  He m at ol o g y Tests 
T he he mat ol o g y pa nel will be perf or me d at t he Ce ntral La b orat or y o n sa m ples c ollecte d at  
Scree ni n g,  Baseli ne ( if Scree ni n g tests w ere o bt ai ne d > 7 d a ys  fr o m Bas eli ne ), Wee k [ADDRESS_1183426] of t he f oll o wi n g tests:  
• Re d bl o o d cell c o u nt ( R B C) 
• He mat ocrit  
• He m o gl o bi n 
• R B C i n dices  
• Platelet c o u nt  
• W hite bl o o d cell c o u nt ( W B C) 
• W B C differe ntial c o u nt 
6. 2. 5. 3.  Cli nic al C he mistr y L a b or at or y Tests 
T he cli nical c h e mistr y p a nel will be perf or m e d at t he Ce ntral La b orat or y o n sa m ples c ollecte d at 
Scree ni n g, Baseli ne ( if Scree ni n g tests w ere o bt ai ne d > 7 d a ys  fr o m Bas eli ne ), Wee k [ADDRESS_1183427] of t he f oll o wi n g t ests: 
• Ser u m s o di u m 
• Ser u m p otassi u m 
• Ser u m c hl ori de 
• Ser u m bicar b o nat e ( C O 2) 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 3 5  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  • Ala ni ne a mi n otra nsf eras e  ( A L T)  
• As partate a mi n otra nsferase ( A S T)  
• T otal bilir u bi n  
• Al kali ne p h os p hatase 
• T otal pr otei n  
• Ser u m creati ni ne  
• Bl o o d urea nitr o ge n ( B U N) 
6. 2. [ADDRESS_1183428] or y  
De m o gra p hic i nf or mati o n will be c ollecte d at Scr ee ni n g a n d i ncl u de t h e f oll o wi n g i nf or mati o n 
t hat will be rec or d e d i n t he Electr o nic Cas e Re p or t F or m ( e C R F ): 
• Birt h date  
• Se x  
• Race  
• Et h nic gr o u p 
• S m o ki n g hist or y 
• Alc o h ol c o ns u m pti o n  
At eac h st u d y visit, i nteri m  me dical hist or y will be o btai ne d a n d rec or d e d.  
6. 2. 6. 2.  P h ysic al E x a mi n ati o n 
A c o m plete p h ysical e x a mi nati o n will be perf or m e d a n d all a b n or m alities n ote d i n t he e C R F at 
Scree ni n g , Baseli ne , t he 2- wee k  p ost- R T visit , a n d  t he 6- wee k  p ost- R T visit . 
6. 2. 6. 3.  Q u alit y of Lif e Q uesti o n n aire  
A Q ualit y of Life Q u esti o n naire will be c o m plete d b y eac h p atie nt at Baseli ne, [ADDRESS_1183429] u g treat me nt ( [ADDRESS_1183430]- R T) a n d re vi e we d a n d e nter e d b y t h e site 
pers o n nel i nt o t he e C R F. T he E O R T C Q L Q - C 3 0 ( versi o n 3) a n d t he E O R T C Q L Q - H & N [ADDRESS_1183431]- R T visit . 
Vital si g ns will i ncl u de t he f oll o wi n g meas ure m e nts: 
• Heart r ate  
• Res pi[INVESTIGATOR_1305] y rate  
• Te m perat ur e  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 3 6  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  • Bl o o d press ur e (seate d ) 
• Wei g h t 
6. 2. 6. 5.  Hei g ht  a n d B o d y M ass I n de x ( B MI)  
Hei g ht will be c ollecte d  at Bas eli ne o nl y  a n d B o d y Mass I n d e x ( B MI) a ut o maticall y calc ulate d . 
6. 3.  Visit Sc he d ule  
6. 3. [ADDRESS_1183432] be re vie we d t o ass ur e t hat t he patie nt meets all 
e ntr y criteri a . Pr oce d ures t o be d o ne at t his visit are: 
• O btai n I nf or me d C o nse nt F or m (I C F) si g nat ur e 
• Ass ure t hat t he i nitial t u m or i ma gi n g is  c o m pati ble wit h R E CI S T Criteria  ( C T, M RI, or 
P E T sca ns)  
• Ass ure t hat t he t u m or was e val uate d f or H P V stat us  
• Assess me nt of e ntr y criteria  
• C o m plete Me dical Hist or y  
• C o m plete P h ysi cal E x a mi nati o n  
• Vital Si g ns  
• Ser u m H C G pre g na n c y t est ( w o me n o nl y) 
• He mat ol o g y Pa n el   
• Cli nical C he mistr y Pa n el  
6. 3. [ADDRESS_1183433] or y ta ke n t o ass ure t h at t he patie nt meets all e ntr y criteria. If t he patie nt still q ualifies,  t he y 
will u n der g o t he f oll o wi n g pr o ce d ur es: 
• I nteri m Me dical Hist or y  
• Ra n d o mizati o n 
• Vital si g ns  
• A d verse e ve nts ( be gi n c ollecti n g after r a n d o mizati o n) 
• P h ysical E x a m   
• He mat ol o g y Pa n el  (if m ore t ha n 7 d a ys  fr o m Scr ee ni n g sa m ple) 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 3 7  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  • Cli nical C he mistr y Pa n el  (if m ore t ha n 7 d a ys  fr o m Scree ni n g sa m ple)  
• Cli nical e val uati o n of m uc ositis ( W H O Sc ore)  
• Q ualit y of Lif e  assess me nt  
• Ser u m Pre g n a nc y  (if m or e t ha n 7 d a ys  fr o m Scree ni n g sa m ple)  
• Hist or y of p ai n a n d o pi [INVESTIGATOR_2495] d me dicati o n use 
• Assess me nt of I nf ecti o ns 
6. 3. [ADDRESS_1183434] u d y visit da ys occ ur t wice wee kl y ( e ver y 3 da ys +/- 1 da y) t hr o u g h t he c o m pleti o n of R T. T he 
first st u d y visit m ust occ ur wit hi n [ADDRESS_1183435] u g a d mi nistrati o n visits, t he 
f oll o wi n g will be p er f or me d : 
• I nteri m Me dical Hist or y  
• Vital si g ns  
• A d verse e ve nts  
• Cli nical e val uati o n of m uc ositis ( W H O Sc ore)  
• Rec or d details of p erc uta ne o us e n d osc o pic gastr ost o m y ( P E G ) t u be us e (if a p plica ble)  
• St u d y Dr u g a d mi nistrati o n  
• Hist or y of p ai n a n d o pi [INVESTIGATOR_2495] d use 
• Assess me nt of I nf ecti o ns 
• Q ualit y of Lif e assess me nt  ( Wee k 4 o nl y) 
• I n a d diti o n t o t he a b o ve, r o uti ne safet y la b orat ories will be o btai ne d d uri n g Wee ks 3 a n d 
6 f or:  
o Bl o o d c ollecti o n f or h e m at ol o g y a n d cli nical c he mistr y pa nel 
6. 3. [ADDRESS_1183436] u d y visit da ys occ ur t wice wee kl y ( e ver y 3 da ys ± 1 da y) f or t he first wee k  f oll o wi n g 
c o m pleti o n of R T. At t hese st u d y dr u g a d mi nistrati o n visits, t he f oll o wi n g will be p er f or me d:  
• I nteri m Me dical Hist or y  
• Vital si g ns  
• A d verse e ve nts  
• Cli nical e val uati o n of m uc ositis ( W H O Sc ore)  
• Rec or d details of gastr ost o m y t u be use (if a p plica ble ) 
• St u d y Dr u g a d mi nistrati o n  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 3 8  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  • Hist or y of p ai n a n d o pi [INVESTIGATOR_2495] d use 
• Assess me nt of I nf ecti o ns 
6. 3. [ADDRESS_1183437] u d y visit da ys occ ur t wice wee kl y ( e ver y 3 da ys +/- 1 da y) f or t he sec o n d wee k  f oll o wi n g 
c o m pleti o n of R T. At t hese st u d y dr u g a d mi nistrati o n visits, t he f oll o wi n g will be p er f or me d:  
• I nteri m Me dical Hist or y  
• Vital si g ns  
• A d verse e ve nts  
• Cli nical e val uati o n of m uc ositis ( W H O Sc ore)  
• Rec or d details of gastr ost o m y t u be use (if a p plica ble)  
• St u d y Dr u g a d mi nistrati o n  
• Hist or y of p ai n a n d o pi [INVESTIGATOR_2495] d use 
• Assess me nt of I nf ecti o ns 
• I n a d diti o n, t he fi nal da y of st u d y dr u g a d mi nistrati o n ( last visit Wee k [ADDRESS_1183438]- R T) t he 
f oll o wi n g a d diti o nal assess me nts will be perf or me d: 
• Bl o o d c ollecti o n f or h e m at ol o g y a n d cli nical c he mistr y pa nels 
• P h ysical e x a mi nati o n  
• Q ualit y of Lif e assess me nt  
6. 3. [ADDRESS_1183439] -R T Visit   
Patie nts will be see n o nce i n t he t hir d wee k f oll o wi n g c o m pleti o n of R T f or t he f oll o wi n g: 
• I nteri m Me dical Hist or y  
• Vital si g ns  
• A d verse e ve nts  
• Cli nical e val uati o n of m uc ositis ( W H O Sc ore)  
• Rec or d  details of gastr ost o m y t u be use (if a p plica ble)  
• Hist or y of p ai n a n d o pi [INVESTIGATOR_2495] d use 
• Assess me nt of I nf ecti o ns 
6. 3. [ADDRESS_1183440] -R T Visit  
Patie nts will be see n o nce i n t he f o urt h wee k f oll o wi n g c o m pleti o n of R T f or t he f oll o wi n g: 
• I nteri m Me dical Hist or y  
• Vital si g ns  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 3 9  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  • A d verse e ve nts  
• Cli nical e val uati o n of m uc ositis ( W H O Sc ore ) 
• Rec or d details of gastr ost o m y t u be use (if a p plica ble)  
• Hist or y of Pai n a n d o pi [INVESTIGATOR_2495] d use 
• Assess me nt of I nf ecti o ns 
• Bl o o d c ollecti o n f or h e m at ol o g y a n d cli nical c he mistr y pa nels 
6. 3. [ADDRESS_1183441]- R T Visit  ( o n l y t o be d o ne if W H O sc ore is ≥ [ADDRESS_1183442] -R T)  
Patie nts will be see n o nce i n t he fift h wee k f oll o wi n g c o m pleti o n of R T if t he patie nt ha d a n O M 
gr a de i n Wee k [ADDRESS_1183443]- R T t hat was ≥ 2  f or t he f oll o wi n g: 
• I nteri m Me dical Hist or y  
• Vital si g ns  
• A d verse e ve nts  
• Cli nical e val uati o n of m uc ositis ( W H O Sc ore)  
• Rec or d details of gastr ost o m y t u be use (if a p plica ble)  
• Hist or y of Pai n a n d o pi [INVESTIGATOR_2495] d use 
• Assess me nt of I nf ecti o ns 
6. 3. [ADDRESS_1183444]- R T Visit  
Patie nts will be see n o nce i n t he si xt h wee k f oll o wi n g c o m pleti o n of R T f or t he f oll o wi n g: 
• I nteri m Me dical Hist or y  
• Vital si g ns  
• A d verse e ve nts  
• Cli nical e val uati o n of m uc ositis ( W H O Sc ore)  
• Rec or d details of gastr ost o m y t u be use (if a p plica ble)  
• Bl o o d c ollecti o n f or h e m at ol o g y a n d cli nical c he mistr y pa nels 
• Hist or y of p ai n a n d o pi [INVESTIGATOR_2495] d use 
• Assess me nt of I nf ecti o ns 
• P h ysical e x a mi nati o n  
• Ser u m H C G pre g na n c y t est ( w o me n o nl y) 
6. 3. 1 0  M o nt hl y  ( [ADDRESS_1183445] -R T ) F oll o w- u p C o nt acts  
All patie nts will be c o ntacte d at least o nce per m o nt h  ( ± 2 wee ks)  t hr o u g h 1 1 m o nt hs (e x ce pt f or 
t he 1 2 wee k/ 3 m o nt h f oll o w- u p visit) f oll o wi n g c o m pleti o n of t heir last R T treat me nt t hr o u g h 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 4 0  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183446] , t he f oll o wi n g i nf or mati o n t hat will be 
e ntere d i nt o t he e C R F:  
• Vital stat us  
• E vi de nce of rec urre n ce of t he pri mar y t u m or 
• I nitiati o n of a d diti o n al  a nti -ca ncer t her a p y  
6. 3. 1 1  1 2 w ee ks ( 3 -M o nt h ) P ost -R T F oll o w -u p Visit  
Patie nts will ha ve a cli nic visit  at 1 2 wee ks ( ± 3 w ee ks)  a n d t h e f oll o wi n g will be perf or me d: 
• I nteri m Me dical Hist or y  
• Hist or y of p ai n a n d o pi [INVESTIGATOR_2495] d use 
• Re peat of t h e sa m e sca ns use d at t he i nitial t u m or sta gi n g t o be use d i n a R E CI S T 1. 1 
c o m paris o n 
• Rec or d of t u m or stat us i n cl u di n g e vi d e nce of t u m or rec urre n ce a n d a d diti o n al  a nti -ca n cer  
t hera pi[INVESTIGATOR_014]  
6. 3. [ADDRESS_1183447] u d y visit at 1 2 m o nt hs ( ± 2 8 da ys) p ost -R T a n d t he f oll o wi n g will be 
perf or me d : 
• I nteri m Me dical Hist or y  
• Hist or y of p ai n a n d o pi [INVESTIGATOR_2495] d use 
• E val uati o n of t u m or stat us 
• Re peat of t he sa m e sca ns use d a t t he i nitial t u m or sta gi n g t o be u se d i n a R E CI S T 1. 1 
c o m paris o n  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 4 1  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183448] meet all  of t he f oll o wi n g criteria:  
1.  Willi n g a n d a ble t o u n dersta n d a n d si g n a n i nf or m e d c o nse nt 
2.  Males or fe m ales a ge grea ter t ha n or e q ual t o 1 8 years 
3.  Bi o ps y- pr o ve n s q u a m o us cell car ci n o ma of t he oral ca vit y or or o p har y n x wit h o ut dista nt 
or ga n metastases  t h at has bee n e v al uate d f or h u ma n pa pi[INVESTIGATOR_4382] o ma vir us ( H P V) 
4.  Sc he d ule d t o recei ve cis plati n c he m ot hera p y of 8 0 - 1 0 0 m g/ m² gi ve n e v er y t hir d wee k  
5.  Sc he d ule d t o recei ve a c o nti n u o us c o urse of c o n v e nti o nal e xter nal bea m irr a diati o n 
deli vere d b y I M R T as si n gle d ail y fracti o ns of 2. [ADDRESS_1183449] 2 oral sites (r etr o m olar tri g o n e, 
b uccal m uc osa, fl o or of m o ut h, t o n g ue, or s oft palate), wit h eac h site recei vi n g ≥ 5 5 G y  
7.  All w o me n of c hil d beari n g p ote ntial ( W O C B P) a n d males wit h fe male p art ners w h o ar e 
W O C B P m ust a gree t o t he use of effecti ve c o ntr ace pti o n d uri n g t he tri al  
 
• W o me n are c o nsi der e d t o be W O C B P f oll o wi n g me narc h e a n d u ntil bec o mi n g p ost- 
me n o pa usal u nless per m a ne ntl y sterile ( h yster ect o m y, bilater al sal pi n gect o m y a n d 
bilateral o o p h orect o m y). A p ost me n o pa usal state is defi ne d as n o me ns es f or [ADDRESS_1183450] u g 
a d mi nistrati o n.  
 
• Ac ce pt a ble c o ntr ace pti ve met h o ds f or W O C B P ar e t h ose t hat ac hie v e a f ail ure rat e of 
less t ha n 1 % per year a n d i ncl u de:  
o C o m bi ne d (estr o ge n a n d pr o gest o ge n c o ntai ni n g) h or m o nal c o ntrace pti o n 
ass ociate d wit h i n hi biti o n of o v ulati o n: 
  Oral  
 I ntr a va gi nal 
 Tra ns der m al  
o Pr o gest o ge n - o nl y h or m o nal c o ntrace pti o n ass ociate d wit h i n hi biti o n of 
o v ulati o n:  
 Oral  
 I njecta ble  
 I m pla nta bl e 
o I ntr a uteri ne d e vice (I U D)  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 4 2  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183451] e m ( I U S)  
o Bilater al t u bal occl usi o n  
o Vasect o mize d  part ner 
o Se x ual a bsti ne nce de fi ne d as refrai ni n g fr o m het er ose x ual i nterc o urse 
d uri n g t he e ntire peri o d of ris k ass ociate d wit h t he st u d y treat me nts 
• Male s u bject s s h o ul d use c o n d o ms d uri n g tr eat me nt a n d f or  [ADDRESS_1183452] E xcl usi o n  Criteri a  
Patie nts wit h a n y of t he f oll o wi n g criteria ar e N O T  eli gi ble f or e nr oll me nt:  
1.  C urre nt m uc ositis  
2.  C urre nt  cli nicall y si g nifi ca nt  acti ve i nf ecti o n  t hat i n t he o pi [INVESTIGATOR_9384] o n of t he I n v esti gat or w o ul d 
ma ke t he m a n u nfit partici pa nt i n t he trial  
3.  Pla n ne d t o re cei v e Er bit u x ™ ( Cet u xi ma b) or si milar tar gete d t her a p y bet wee n baseli ne 
a n d [ADDRESS_1183453]- ra diati o n t hera p y  
4.  C urre nt use of pr o hi bite d t hera pi[INVESTIGATOR_851179] d i n Secti o n 8. 2  
5.  Pri or ra diati o n t o t he hea d a n d nec k 
6.  C he m ot hera p y treat me nt wit hi n t he pre vi o us 1 2 m o nt hs 
7.  T u m ors of t he li ps, si n uses, sali var y gla n ds, nas o p har y n x, h y p o p har y n x, or lar y n x  
8.  E vi de nce of si g nifica nt r e nal, he patic, h e mat ol o gi c, or i m m u n ol o gic disease deter mi ne d 
b y a n y o n e of t he f oll o wi n g: ( t he b el o w ar e e x a m ples of e vi de nce of si g nifi ca nt disease, 
n ot re q uire d tests)  
a.  Esti mate d creati ni ne cleara nce < 3 0 m L/ mi n  
b.  A L T or A S T le vel gr eater t ha n 1 0 -f ol d t he u p per li mit of n or mal or t otal bilir u bi n 
gr eater t ha n 3 -f ol d t he u p per li mit of n or mal 
c.  Ma nifestati o ns of e n d- sta ge li ver disease, s u c h as ascites or he p atic 
e nce p h al o pat h y  
d.  T hr o m b oc yt o p e nia (less t ha n 6 0, 0 0 0 cells/ m m 3) 
e.  C D 4 + T cell c o u nt bel o w 2 0 0 cells per µ L ( verificati o n o nl y re q uire d if t here i s a 
cli nical dia g n osis of HI V i nfecti o n)  
9.  E vi de nce of i m me diate life -t hreate ni n g diseas e or a life e x pecta nc y of less t ha n [ADDRESS_1183454] or q ualit y of t he data 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 4 3  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183455] a w al Criteri a  
Patie nts ha ve t he ri g ht t o wit h dra w fr o m t his trial at a n y ti m e ( as descri be d i n t he i nf or me d 
c o nse nt d oc u me nt) wit h o ut prej u dice t o f urt her car e. A n i n vesti gat or ma y wit h dra w a patie nt 
fr o m t he st u d y at a n y ti me f or a n y of t he f oll o wi n g r eas o ns:  
• T he patie nt wit h dra ws his/ her c o nse nt or ref us es f oll o w- u p e val uati o ns.  
• T he patie nt is l ost t o f oll o w - u p a n d will n ot atte n d f urt her st u d y visits. 
• T he i n vesti gat or deter mi nes t hat f urt her p artici pati o n w o ul d be detri me ntal t o t he 
patie nt’s healt h or w ell -b ei n g.  
• T he patie nt fails t o c o m pl y wit h t he st u d y re q uir e me nts t o  ca use har m t o s elf or seri o usl y 
i nterfer e wit h t he vali dit y of t he st u d y res ults.  
• T he fe mal e patie nt bec o mes pre g na nt d uri n g t he treat me nt peri o d. I n t his case, treat me nt 
s h o ul d be halte d a n d t he patie nt f oll o we d u ntil t he e n d of t he pr e g na nc y. If a c hil d is 
b or n, t he i nfa nt s h o ul d be f oll o we d t hr o u g h at least 6 m o nt hs of a ge. 
• At t he discreti o n of t he site i n vesti gat or if h e/s he f eels t hat it is i n t he best me dical 
i nterest of t he patie nt.  
• T he patie nt misses m ore t ha n 5 c o nsec uti ve s c he d ule d R T sessi o ns. 
• Patie nts wit h dra w n fr o m t he st u d y will ha ve as ma n y of t he trial assess me nts c o m plete d 
as t he patie nt per mits i ncl u di n g bl o o d tests  a n d sca ns b ut n ot i ncl u di n g O M sc ori n g. All 
ot her t hera pi [INVESTIGATOR_014] i ncl u di n g ra diati o n t hera p y, t h e t y p e a n d fr e q ue n c y of c h e m ot hera p y, a n d 
oral treat me nts  will re mai n at t he discreti o n of t he cli nical tea m.  Patie nts will be ce ns ore d 
i n t he efficac y a n al ys es at t he ti me of wit h dra wal.  
• Patie nts wit h dra w n fr o m t he trial will n ot be re place d b ut e nr oll me nt will c o nti n ue u ntil a 
mi ni m u m of [ADDRESS_1183456] u d y ma y b e ter mi n ate d earl y f or a n y of t he f oll o wi n g reas o ns: 
• A healt h a ut h orit y or D M C  re q uests ter mi nat i o n of t he st u d y. 
• It has b ee n d eter mi ne d t h at t he ris k le vel ass oci ate d wit h t he e x peri me ntal dr u g is 
si g nifica nt a n d warra nts t er mi nati o n of t he st u d y.  
• S oli ge ni x , f or reas o ns ot her t ha n saf et y, ma y ter mi nate t he st u d y at a n y ti me b y writte n 
n otice of i nte n de d ter mi nati o n pr o vi de d at least t hirt y ( 3 0) da ys pri or t o ter mi nati o n. 
• T he i n vesti gat or or I R B/ E C, f or reas o ns ot h er t ha n safet y, ma y ter mi nat e p artici pati o n of 
t his site i n t he st u d y b y writte n n otice of i nte n de d t er mi nati o n pr o vi de d at least t hirt y ( 3 0) 
da ys pri or t o ter mi nati o n.  
• A n y ot her cla us e descri be d i n t he i n di vi d ual site St u d y A gr ee me nt ( e. g., if G C Ps or ot her 
re g ulat or y pr o ce d ur es ar e n ot f oll o we d; if e nr oll me nt rate is n ot s ufficie nt t o meet st u d y 
g oa ls).  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 4 4  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183457] da y of 
R T  a n d t he n t wice w ee kl y ( e ver y  t hir d d a y ± 1 da y) t hereafter u ntil [ADDRESS_1183458] u d y- s pecifie d pr ot oc ols. All s u bjects will recei ve c o nc o mita nt cis plati n c h e m ot h era p y ( 8 0 - 1 0 0 
m g/ m 2) f or treat me nt of ca ncer of t he or al ca vit y a n d or o p har y n x.  
C o nc o mita nt dr u gs ta ke n b y t he p atie nt d uri n g t h e treat me nt p hase a n d t hr o u g h t he 6- wee k  p ost- 
R T  visit s h o ul d be rec or d e d i n t he e C R F. I n ge n er al, t he ge ner i c na me of t he dr u g  s h o ul d be 
use d. Dr u g na mes, es peci all y c o m bi nati o n pr e par ati o ns, s h o ul d n ot i ncl u de t he d ose of eac h 
c o m p o ne nt dr u g i n t he na me b ut s h o ul d be n ote d i n t he d ose- Na m e: “ D oc usate/ Se n na” D os e 
“ 5 0/ 8. 6” rat her t ha n N a me: “ D oc usat e 5 0 m g - Se n na 8. 6 m g”. C o m p o ne nts of a n y m o ut h was h 
prescri be d s h o ul d b e liste d- i nstea d of “ M a gic M o ut h was h” rec or de d “ M o ut h was h- 
Maal o x/ Li d o cai ne”.  
T he f oll o wi n g m e dicati o ns/t hera pi[INVESTIGATOR_014] s h o ul d N O T  be use d i n e nr olle d p atie nts  (fr o m baseli ne 
t hr o u g h [ADDRESS_1183459]- R T) : 
• A mif osti ne ( Et h y ol ®)  
• Be nz y d a mi ne h y dr o c hl ori de  
• Cet u xi ma b ( Er bit u x ®) 
• Ce vi meli ne h y dr o c hl ori d e ( E v o x ac ®)  
• Gl uta mi ne as a pr o p h ylactic a ge nt f or m uc ositis  
• De vices f or m uc ositis i ncl u di n g Gel Clair, M u Gar d, E pi[INVESTIGATOR_119594] a n d Ca p h os ol 
• G M - C S F (e. g., Le u ki ne ®) 
• I L - 1 1 ( N e u me ga ®)  
• ‘ Ma gic m o ut h was h’, ‘ Miracle m o ut h was h’ or ot h er m o ut h was h s ol uti o ns c o ntai ni n g a n y 
of t he f oll o wi n g:  
• C hl or he xi di ne  
• H y dr o ge n per o xi de  
• Di p he n h y dra mi ne  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 4 5  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  • Tetrac ycli ne  
• Palifer mi n ( Ke pi [INVESTIGATOR_100214] n ce ®) or ot her ker ati n oc yte or fi br o blast gr o wt h fact or 
• Pil ocar pi [INVESTIGATOR_050] h y dr oc hl ori d e ( Sala ge n ®)  
• P o vi d o ne-i o di ne ri nses  
• Ster oi d ri nses  
• S ucralfate i n s us pe nsi o n f or m ( use of s u cralf ate ta blets is n ot pr oscri be d)  
• Ot her  bi ol o gic  res p o ns e  m o difiers  – e x ce pt  he mat o p oietic  gr o wt h  f act ors  f or  t h e  
ma na ge me nt of a ne mia or m yel os u p press i o n 
• L o w le v el laser t h era p y   
• Ot her i n vesti gati o nal a ge nts f or m uc ositis  
8. 3.  Tre at me nt C o m pli a nce  
Patie nts will be treate d wit h a n I V i nf usi o n wit nesse d b y site p ers o n nel d uri n g t heir d ail y 
ra diati o n treat me nt cli nic a p p oi nt me nts a n d, t heref ore, c o m plia nce wit h  st u d y cli nic visits is 
e x pecte d t o be hi g h w hile t he c he m or a diati o n treat me nts are c o nti n ui n g.  
Ever y eff ort will be ma d e b y t h e patie nt a n d t he st u d y staff t o e ns ur e t hat  patie nts ca n  c o m plete 
t he assi g n e d tas ks of t he trial o n sc he d ule a n d as p er pr ot oc ol pri or t o b ei n g c o nse nte d. E ver y 
eff ort s h o ul d be ma d e, w he n me dicall y res p o nsi bl e, t o a v oi d treat me nt br ea ks or dela ys. 
8. 4.  R a n d o miz ati o n a n d Bli n di n g  
Patie nts  will be ra n d o mize d 1: 1 t o S G X 9 4 2 : place b o usi n g a r a n d o mizati o n c o de ge n erate d b y a n 
i n de pe n de nt statisticia n. Ra n d o mizati o n will be perf or me d usi n g a n I nter acti ve We b Res p o nse 
S yste m (I W R S) i n a d o u ble- bli n d fas hi o n. Eac h vial of S G X [ADDRESS_1183460] b o vials will be s u p plie d a n d la bele d wit h a u ni q ue bli n de d i de ntif yi n g c o d e. T he I W R S 
will assi g n vial(s) of t h e a p pr o priate st u d y material t o be use d f or eac h pati e nt a n d eac h i nf usi o n 
usi n g t his bli n de d c o de.  
Patie nts will be stratifie d at ra n d o mizati o n b y H P V stat us , prese nce of a gastr ost o m y t u be at 
ra n d o mizati o n, a n d st u d y site.  
Gi ve n t he e xtre mel y s h ort half life of S G X 9 4 2 ( mi n utes), it is a ntici pate d t hat k n o wle d ge of 
w het her t he p atie nt recei ve d place b o or S G X 9 4 2 will rarel y be n e e de d. If, h o we ver, t he PI a n d/ or 
t he pri mar y care cli nical tea m belie ve t hat t his i nf or mati o n is necessar y t o o pti mall y tr eat a n 
e nr olle d patie nt, t he cli ni cal data ma n a ge me nt tea m ( D S G) s h o ul d be c o ntacte d ( 2 4 h o ur/ 7 da y 
a vaila bilit y) usi n g t he c o ntact di recti o ns a v aila ble i n t he e C R F p ortal. T he st u d y dr u g assi g n me nt 
f or t hat patie nt will be deter mi ne d a n d c o nfir mati o n of t he st u d y dr u g recei ve d will be 
i m me diatel y se nt.  
 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 4 8  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183461]- R T.  
T he d urati o n of S O M is t he pri mar y e n d p oi nt f or t his cli nical trial.  
SO M is defi ne d a W H O sc ore of ≥ 3 ( 3 or 4). Res ol uti o n of S O M is defi ne d as t he first 
assess me nt wit h a W H O sc ore < 3 wit h n o f urt her re p orts of a W H O gra de of ≥ 3. T he d urati o n of 
S O M is defi ne d as t he n u m ber of da ys fr o m t he first W H O sc ore ≥ [ADDRESS_1183462]  da y wit h W H O 
sc ore ≤ 3 wit h n o f urt her occ urr e nce of W H O sc or e ≥ 3. If t he patie nt h as n ot met t he 
re q uire me n ts f or res ol uti o n of S O M b y t he 6- wee k p ost- R T visit, he/s he will be c o nsi dere d 
ce ns ore d at t hat visit ( or p oi nt of disc o nti n uati o n of t he st u d y, if t he p atie nt disc o nti n ues pri or t o 
t hat ti me p oi nt). T o facilitate cal c ulati o n of a l o g -r a n k test wit h o ut ce ns ori n g patie nts wit h 
desira ble o utc o mes ( n o S O M), patie nts w h o d o n ot e x perie nce S O M  will be treate d as ha vi n g a 
d urati o n of S O M  of 0. 0 1 da ys . T h e pri mar y e n d p oi nt a nal ysis will be c o n d u cte d i n t he mI T T 
p o p ulati o n. 
1 0. 2.  Sec o n d ar y Effic ac y  E n d p oi nts  
1 0. 2. 1  Pri m ar y Sec o n d ar y A n al yses 
T he pri mar y sec o n d ar y e n d p oi nts are liste d bel o w  i n hierar c hical or der  a n d will be c o m pare d i n 
t he mI T T p o p ul ati o n. 
1 0. 2. 1. 1.  Se verit y -w ei g hte d D ur ati o n of S O M ( Are a -U n der t he  S O M -Ti me  C ur v e)  
T he se verit y - wei g hte d d urati o n of S O M will be calc ulate d b y t he A U C of t he S O M vers us ti me 
c ur ve. T his will be calc ul ate d b y t he f or m ula f or b aseli ne (t a) t o ti me t he last re p orte d W H O 
sc ore r ec or d e d (t b):  
 ( ) ( )( ) ∑−
=+ + − + = − 1
1 1 
2b
a i i i i i 
a b t t y y t t A U C  
w here t i re pr ese nts t he date of t he i t h  W H O assess me nt, a n d y i re prese nts t h e val ue of t he i t h  W H O 
assess me nt f or W H O ass ess me nts f or w hic h t he s c ore is ≥ 3.  
1 0. 2. 1. 2.  Se verit y -w ei g hte d D ur ati o n of U O M ( Are a -U n der t he S O M -Ti me C ur ve)  
T he  se verit y - wei g hte d d urati o n of U O M will b e calc ulate d b y t he A U C of t he U O M vers us ti me 
c ur ve. T his will be calc ul ate d b y t he f or m ula f or b aseli ne (t a) t o ti me t he last re p orte d W H O 
sc ore r ec or d e d (t b):  
 ( ) ( )( ) ∑−
=+ + − + = − 1
1 1 
2b
a i i i i i 
a b t t y y t t A U C  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 4 9  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  w here t i re pr ese nts t he date of t he i t h  W H O assess me nt, a n d y i re prese nts t h e val ue  of t he i t h  W H O 
assess me nt f or W H O ass es s me nts f or w hic h t he s c ore is ≥ [ADDRESS_1183463] o ne W H O sc ore ≥ 3.  
1 0. 2. 1. 4.  Q u alit y of Lif e  
A Q ualit y of Life Q u esti o n naire ( Q o L)  will be c o m plete d b y eac h p atie nt at Baseli ne, [ADDRESS_1183464] u g treat me nt ( [ADDRESS_1183465]- R T) a n d re vie we d a n d e ntere d b y t he site 
pers o n nel i nt o t he e C R F. T he E O R T C Q L Q - C 3 0 ( versi o n 3) a n d t he E O R T C Q L Q- H & N [ADDRESS_1183466] u d y pers o n nel will rec or d t he a m o u nt of o pi [INVESTIGATOR_2495] d me dicati o n t hat t he patie nt 
re p orts ha vi n g ta ke n o v er t he pre vi o us 2 4 h o urs. E ac h t y pe of me di cati o n a n d w het her it was 
use d beca us e of O M p ai n or ot her t y pes of p ai n will be n ote d i n t he e C R F. Eac h o pi [INVESTIGATOR_2495] d d ose will 
be c o n vert e d t o a n “ oral m or p hi ne d ose e q ui vale nt d ose” a n d t he t otal a m o u nt of o pi [INVESTIGATOR_2495] d use d f or 
eac h p atie nt s u m me d o ver eac h visit fr o m b aseli ne t o [ADDRESS_1183467] ual n u m ber of treat me nt brea k da ys ( ≥ 3 da ys  
per  brea k) t hr o u g h t he fi nal R T treat me nt a n d c o m pari n g t hes e bet w ee n tr eat me nt gr o u ps. 
1 0. 2. 2. 2.  D ur ati o n of S O M i n t he I T T P o p ul ati o n 
Usi n g t he a b o ve defi niti o ns, t he d urati o n of S O M will be c o m pare d b et wee n treat me nt gr o u ps i n 
all patie nts ra n d o mize d (I T T p o p ul ati o n). 
1 0. 2. 2. 3.  D ur ati o n of Ulcer ati ve Or al M uc ositis ( U O M)  
U O M is defi ne d as a W H O sc ore ≥ 2.  Res ol uti o n of U O M is defi ne d as t he first assess me nt wit h 
a W H O sc ore < 2 wit h n o f urt her r e p orts of a W H O gra de of ≥ 2. T he d ur ati o n of U O M is defi ne d 
as t he n u m ber of d a ys fr o m t he first W H O sc ore ≥ [ADDRESS_1183468]  da y wit h W H O sc ore < 2  wit h n o 
f urt her occ u rr e nce of W H O sc ore ≥ 2 . If t he p atie nt has n ot met t he re q uire me nts f or res ol uti o n of 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 5 0  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183469]- R T visit, he/s he will be c o nsi dere d ce ns or e d at t h at visit ( or p oi nt of 
disc o nti n uati o n of t he st u d y, if t he p atie nt disc o nti n ues pri or t o t hat ti m e p oi nt). F or statistical 
reas o ns, patie nts w h o d o n ot e x perie nce S O M  will be treate d as ha vi n g a d urati o n of U O M of 
0. [ADDRESS_1183470] u d y visit, t he patie nt’s assess me nt of t heir pai n o ver t he pr e vi o us [ADDRESS_1183471] oral e x a mi nati o n wit h W H O 
gr a de ≥ [ADDRESS_1183472]  assess me nt wit h a W H O sc ore ≥ 3 ( a n d n ot t o t he firs t assess me nt wit h 
a W H O gra de < 3) wit h n o f urt her r e p ort s of a W H O gra de ≥ [ADDRESS_1183473] u g d oses.  
 
 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 5 1  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  1 1.  A S S E S S M E N T O F S A F E T Y  
1 1. 1.  O ver all Assess me nts  
Safet y i n t his trial will be assesse d  b y t he f oll o wi n g c o m p aris o ns bet wee n treat me nt gr o u ps: 
• Assess me nt of t he i nci de nce, t y pe, a n d b o d y s yste m cate g orizati o n of A Es 
• Assess me nt of t he i nci de nce, t y pe, a n d b o d y s yste m cate g orizati o n of S A Es  
• Assess me nt of t he c h a n ges fr o m baseli ne f or he m at ol o g y para meters, cli nical c he mistr y 
para meters, a n d vital si g ns 
• Assess me nt of t u m or pr o gr essi o n at 1 2 wee ks  a n d 1 2 m o nt hs f oll o wi n g c o m pleti o n of R T  
classifie d usi n g t h e R E CI S T t u m o r stat us s yste m  
• T he i nci de nce a n d se v erit y of i nf ecti o ns gra d e d usi n g C T C A E  criteria  
• Assess me nt of m ortalit y t hr o u g h t he [ADDRESS_1183474]- R T visit. T he PI [INVESTIGATOR_851180] t he se v erit y of t he A E usi n g t h e C T C A E criteria ( A p pe n di x 1). T he A Es will be c o de d 
as t o preferre d t er mi n ol o g y, a n d b o d y s yste m  usi n g t he Me dical Dicti o nar y f or Re g ulat or y 
Acti vities ( Me d D R A) usi n g a c o m p uter a ut o- c o der a n d all assi g n me nts re vi e we d b y  a bli n de d 
me dical re vie wer. T h e n u m ber of e v e nts a n d t he n u m ber of patie nts wit h eac h e ve nt defi ne d b y 
t he pref err e d ter m a n d b y b o d y s yste m cate g or y will be prese nte d. A d diti o n al ta bles will 
c o m pare t he re p ort e d A Es b y pr eferre d ter m a n d b o d y s yste m clas sificati o n classifie d b y 
C T C A E se verit y gra de ( 1 - 5) a n d se p arat el y b y PI [INVESTIGATOR_851181] o ns hi p t o st u d y dr u g. 
[ADDRESS_1183475]- R T visit.  T he SA Es will 
be c o de d as t o pref err e d ter mi n ol o g y, a n d b o d y s yste m usi n g t he Me dical Dicti o nar y f or 
Re g ulat or y  Acti vities ( Me d D R A) usi n g a c o m p uter a ut o- c o d er a n d all assi g n me nts re vie we d b y 
a bli n de d me dical r e vie w er. S u m mar y ta bles i ncl u di n g t he n u m ber of e v e nts a n d t he n u m ber of 
patie nts wit h eac h e v e nt defi ne d b y t he pr eferre d t er m a n d b y b o d y s yste m cate g or y will be 
prese nte d. A d diti o nall y, t he re p ort e d S A Es b y pref erre d t er m a n d b o d y s yst e m classificati o n 
classifie d b y C T C A E se v erit y gra de ( 1 -5) a n d se p aratel y b y PI [INVESTIGATOR_851182] o ns hi p t o 
st u d y dr u g. A n arr ati ve s u m mar y of t he patie nt’s S A E will be i ncl u de d i n t he fi nal Cli nical St u d y 
Re p ort. 
1 1. 1. 3  Assess me nt of L a b or at or y a n d Vit al Si g ns 
Eac h o f t he l a b orat or y t ests o utli ne d i n Secti o n 6. 2. 5  a n d eac h of t he vital si g ns o utli ne d i n 
Secti o n 6. 2. 6. 4  will be s u m marize d f or eac h  c ollecti o n peri o d b y tr eat me nt gr o u p as:  
• Gr o u p mea n 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 5 2  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  • Gr o u p sta n dar d d e viati o n 
• Gr o u p me dia n 
• Gr o u p ra n ge 
A d diti o nall y, eac h e v al uati o n will be s u m marize d as a c ha n ge fr o m b aseli n e f or eac h p atie nt b y 
treat me nt gr o u p as:  
• Gr o u p mea n 
• Gr o u p sta n dar d d e viati o n 
• Gr o u p me dia n 
• Gr o u p ra n ge 
Usi n g t he Ce ntr al La b or at or y’s n or mal ra n ges a n d sta n dar d ta ble of n or mal vital si g ns, eac h 
assess me nt will be classifie d as “ n or m al”, “l o w ”, or “ hi g h ” a n d s hift ta bles f or eac h par a meter 
s h o w n of eac h assess me nt b y treat me nt gr o u p will be dis pla ye d.  
[ADDRESS_1183476] e m as o utli ne d i n Ta ble 9, Ta ble 1 0 , a n d Ta ble 1 1 . T h e perce nt of t he p atie nts 
cate g orize d as h a vi n g a “c o m plete t u m or res p o nse” at [ADDRESS_1183477]- R T will be 
c o m pare d b et wee n t h e tr eat me nt gr o u ps. A d diti o nall y, t he p erce nt of t he patie nts cate g oriz e d as 
ha vi n g a “c o m plet e t u m or res p o nse” or “ p artial t u m or res p o nse” at [ADDRESS_1183478]- R T visit as t o t he pre se nce 
of pr o ba ble cli nical i nfecti o ns. All cli nical dia g n oses of i nfecti o ns will be classifie d as pres u me d 
f u n gal, pres u me d vir al, or pres u me d bacteri al. T he se verit y of eac h i nf ecti o n will be gr a de d 
usi n g t he C T C A E ( A p p e n di x 1). T he i nci de nce of all re p orte d i nf ecti o ns, t he n u m ber of p atie nts 
wit h re p orte d i nfecti o ns, t he n u m ber of pr es u me d f u n gal, t he n u m ber of pres u me d viral a n d t he 
n u m ber of pres u m e d bact erial i nfecti o ns will be c o m pare d bet w ee n tr eat me nt gr o u ps. T h e 
i nci de nce of eac h t y p e of i nfecti o n (f u n gal,  vir al, a n d bacterial) b y se verit y gr a de ( 1 -5) will be 
dis pla ye d.  
[ADDRESS_1183479] date of t he f oll o wi n g:  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 5 3  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  • T he patie nt die d  
• T he patie nt ha d a n i ma gi n g r e p ort of t u m or pr o gressi o n ( R E CI S T 1. 1 e val u ati o n of less 
t ha n “ C o m plete Res p o nse”)  
• T he patie nt c o m plete d t h eir [ADDRESS_1183480] assess me nt.  
1 1. 2.  S afet y P ar a meters  
1 1. 2. 1  A d verse E x perie nce ( A E ) 
A n y n o xi o us or u ni nte n de d e ve nt t hat occ urs i n ass ociati o n wit h t he use of a n i n vesti gati o nal 
a ge nt i n h u ma ns , w het her c o nsi dere d rel ate d  t o t he i nvesti g ati o n al a ge nt or n ot . T his defi niti o n 
e nc o m passes s y m pt o ms or si g ns r e p orte d b y t he s u bject or detecte d b y t he i n vesti gat or or ot h er 
c o m pete nt o bser v er, as w ell as me dicall y i m p orta nt de viati o ns fr o m n or malit y i n t he res ults of 
a ncillar y i n vesti gati o ns. If prese nt at ti me of first d ose of st u d y dr u g, s uc h A Es m ust be rec or d e d 
as part of t he me di cal hist or y.  
Treat me nt -E mer ge nt A d verse E x perie nce : A n A E t hat is ne w i n o nset or a g gr a vate d i n se v erit y 
or fre q u e nc y f oll o wi n g e ntr y i nt o t he st u d y. I n a d diti o n, a n y pat h ol o gical fi n di n g o n p h ysical 
e x a mi nati o n or dia g n ostic pr oce d ure t hat is ne w i n occ urr e nce or e x acer bate d i n c o m paris o n wit h 
t he s u bject's stat us at st u d y e ntr y is c o nsi dere d a treat me nt -e mer ge nt A E if it re q uires a n y 
me dical or s ur gical i nter ve nti o n w hats oe ver (i ncl u di n g, b ut n ot li mite d t o, a d diti o nal dia g n ostic 
pr oce d ur es or alterati o n of prescri be d t her a p y). 
All A Es, w het her j u d ge d t o be relate d or n ot t o t he st u d y dr u g, s h o ul d be r ec or de d i n b ot h t he 
me dical rec or d a n d t he e C R F. T he start a n d r es ol uti o n dates, t he j u d g me nt of t he se verit y of t h e 
A E, t he j u d g me nt of t he r elati o ns hi p of t he A E t o t he st u d y dr u g, t h e acti o n ta ke n f or s u bse q u e nt 
d ose of st u d y dr u g, a n d t he o utc o me s h o ul d be n ote d . 
1 1. 2. 2  Seri o us A d verse E x peri e nce ( S A E)  
A n y A E occ urri n g at a n y d ose t hat res ults  i n a n y of t he f oll o wi n g o ut c o mes: 
• Deat h  
• A life -t hreate ni n g A E  
• Pr ol o n gati o n of e xisti n g h os pi[INVESTIGATOR_1314] o n or s u bse q ue nt nee d f or h os pi[INVESTIGATOR_1314] o n 
• A persiste nt or si g nifica nt disa bilit y/i nca p acit y  
• A c o n ge nital a n o mal y/ birt h defect  
• A me dical or s ur gical i nte r ve nti o n t o pre v e nt o ne of t he a b o ve 
[ADDRESS_1183481] u g  is ass esse d usi n g t he f oll o wi n g defi niti o ns: 
N ot Rel at e d : T he dr u g e x perie nce is clearl y relat e d t o ot her fact ors s uc h as t he 
patie nt’s/s u bject’s cli nical state, t hera pe utic i nter v e nti o ns , or c o nc o mita nt dr u gs.  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 5 4  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  P ossi bl y Rel ate d: T h e dr u g e x perie nce f oll o ws a reas o na bl e se q ue n ce fr o m t he  ti me of dr u g 
a d mi nistrati o n a n d/ or f oll o ws a k n o w n res p o ns e patter n t o t he st u d y dr u g, b ut c o ul d ha ve bee n 
pr o d uce d b y ot her fact ors s uc h as t he patie nt’s/s u bject’s cli nical state, t her a pe utic i nter ve nti o ns, 
or c o nc o mita nt dr u gs. 
Rel ate d: T he dr u g e x perie nce f oll o ws a reas o n a bl e te m p oral se q u e nce fr o m t he ti me of dr u g 
a d mi nistrati o n , f oll o ws a k n o w n res p o nse p atter n t o t he st u d y dr u g, a n d ca n n ot be reas o n a bl y 
e x plai ne d b y ot her fact ors s uc h as t he patie nt’s/s u bject’s cli nical state, t her a pe utic i nter ve nti o ns, 
or c o nc o mita nt dr u gs.  
1 1. 4.  Se verit y of A d verse E ve nt  
A cli nical deter mi nati o n of t he i nte nsit y of a n A E  s h o ul d be d o ne f or all re p orte d A Es. T he 
se verit y assess me nt s h o ul d use t he C T C A E gr a di n g s yste m t hat assess es t he se verit y  of eac h A E 
fr o m gra des 1 - 5. T he gra di n g s yste m ca n b e f o u n d i n A p pe n di x 1. 
1 1. 5.  Re p orti n g A d verse E ve nts  
1 1. 5. 1  A d verse E ve nts  
All A Es t hat occ ur after a n y p atie nt/s u bject has b ee n e nr olle d, b ef or e treat me nt, d uri n g 
treat me nt, or wit hi n 6 wee ks ( ± 4 da ys) f oll o wi n g t he cessati o n of R T treat me nt , w het her or n ot 
t he y are relate d t o t he st u d y, m ust be r ec or d e d i n t he e C R F. All A Es s h o ul d be n ote d i n t he e C R F 
wit hi n 3 da ys of b ei n g rec o g nize d. A n y a d vers e e ve nt t hat is eit her a S A E or p ote ntial S A E 
s h o ul d be ha n dle d wit hi n t he ti mefra mes gi ve n i n secti o n 1 1. 5. 2 , bel o w. Eac h treat me nt -
e mer ge nt A E s h o ul d be r e p orte d s p o nta ne o usl y or i n res p o nse t o ge neral, n o n- directe d 
disc ussi o n wit h t he atte n di n g n urse or p h ysicia n ( e. g., h as t her e bee n a n y c ha n ge i n s u bject stat us 
si nce t he last assess me nt peri o d?).  F or eac h tr eat m e nt -e mer ge nt A E, t he i n v esti gat or s h o ul d 
o btai n all t he i nf or mati o n re q uire d t o c o m plet e t he A E pa ge of t h e cas e re p ort f or m, i n 
acc or d a nce wit h t he g ui deli nes t hat acc o m p a n y it.  
All treat me nt -e mer ge nt A Es, re gar dless of seri o us ness, se verit y, or pr es u me d relati o ns hi p t o 
st u d y t her a p y, m ust be rec or de d usi n g me dical ter mi n ol o g y c o nsiste nt wit h t he s o urce d o c u me nt 
a n d o n t he A E pa ge. W he ne ver p ossi ble, dia g n os es s h o ul d be gi v e n w he n si g ns a n d s y m pt o ms 
are d ue t o a c o m m o n eti ol o g y. I n v esti gat ors m ust r ec or d t heir o pi [INVESTIGATOR_9384] o n c o n cer ni n g t he 
relati o ns hi p of t he A E t o st u d y t her a p y o n t he A E pa ge. 
All treat me nt -e mer ge nt A Es m ust be f oll o we d u ntil res ol uti o n or u ntil t he [ADDRESS_1183482] be 
rec or d e d i n t he s o urce d o c u me nt a n d re p orte d o n t he A E pa ge. T he r es ol uti o n date f or all 
rec or d e d A Es s h o ul d be e ntere d wit hi n 3 da ys of deter mi nati o n t hat t he A E has res ol ve d.  
1 1. 5. 2  Seri o us A d verse E ve nts  
All S A Es t hat occ ur aft er a n y p atie nt/s u bject has b ee n e nr olle d, b ef or e treat me nt, d uri n g 
treat me nt, or wit hi n si x wee ks ( ± 4 d a ys) f oll o wi n g t he last R T , w het h er or n ot t he y are r elate d t o 
t he st u d y, m ust be rec or d e d o n f or ms pr o vi de d i n t h e eC R F.  
W he n t he i n vesti gat or, or trai ne d desi g nee, bec o m es a ware t hat a s eri o us or p ote ntiall y seri o us 
A E (as defi ne d a b o v e) has occ urr e d, t he site m o nit or or Me dical M o nit or m ust be n otifie d 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 5 6  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183483] a n y efficac y d ata i ncl u di n g, b ut n ot li mite d t o t he pri mar y 
a n d sec o n dar y o utc o mes t o  e val uate be n efit t o ris k.  
T he D M C will re vie w u n bli n de d data at t he i nteri m a nal ys es a n d ma k e rec o m me n d ati o ns t o halt 
t he trial f or o ver w hel mi n g efficac y, or s afet y c o n cer ns, or f or f utilit y; c o nti n ue t he trial as 
writte n; or resize t he trial base d o n t h e place b o d ur ati o n of S O M. 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 5 9  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  I n acc or da n ce wit h t he G ui deli nes f or t he M o nit ori n g of Cli nical I n vesti gati o ns prese nte d i n t he 
I nter nati o nal C o nfere nce o n Har m o nisati o n ( I C H ) G ui da nce o n G C Ps ( E 6), S oli ge ni x will select,  
eit her directl y or t hr o u g h s u bc o ntract, q ualifie d i n di vi d uals t o m o nit or t he pr o gress of t he st u d y 
a n d a d her e nce t o pr ot oc ol b y t he i n di vi d ual cli nical sites. 
[ADDRESS_1183484], e vi de n ce f or p ot e ntial 
e nr oll me nt of s uita ble patie nts, a de q uate r esearc h p har mac y s u p p ort, t he pr ese nce of a n I R B / E C  
meeti n g t he l o cal a n d F D A re q uire m e nts, a n d a c o m mit me nt f or trai ni n g of all i n v ol ve d staff o n 
t he pr ot oc ol. 
1 2. 6. 3  Site I niti ati o n Visit  
T he Me dical M o nit or ( or trai ne d des i g nee) will i nitiat e t he st u d y after o n- site trai ni n g of t he 
partici pati n g st aff at t he i nstit uti o n. T o pi[INVESTIGATOR_1102] c o vere d will i ncl u de trai ni n g o n:  
• T he i n vesti gati o nal stat us of t he st u d y dr u g a n d t he re q u ire me nts f or its acc o u nta bilit y  
• Bac k gr o u n d o n t he st u d y dr u g 
• Details of t he pr ot oc ol i n cl u di n g patie nt sel ecti o n, st u d y dr u g a d mi nistrati o n, pr oce d ur es 
t o be perf or m e d, a n d visit sc he d ules 
• Critical nat ure of o btai ni n g i nf or m e d c o nse nt i n acc or da n ce wit h t he D eclarati o n of 
Helsi n ki a n d I C H G ui da nce o n G C Ps ( E 6) bef ore e nr olli n g eac h s u bject i n t he st u d y 
• T he o bli gati o n t o e ns ur e I R B re vi e w a n d a p pr o val f or t he st u d y, i ncl u di n g t he pr ot oc ol, 
a me n d me nts,  I C F a n d a n y a d v ertise me nts, is o btai ne d pri or t o its i nitiati o n at his/ her 
cli nical site, t o e ns ure c o nti n ui n g re vie w of t he st u d y b y t he I R B, a n d t o k ee p S oli ge ni x 
i nf or me d of s uc h a p pr o v al a n d s u bse q ue nt acti o ns c o ncer ni n g t he st u d y 
[ADDRESS_1183485] u g a n d s u p p orti n g r ec or ds will be re vie w e d. A d diti o nall y, t he y 
ass ure t hat all seri o us, lif e -t hreate ni n g or f atal a d v erse e x perie n ces are bei n g r e p orte d 
i m me diatel y [ a n d i n n o case later t h a n t we nt y -f o ur ( 2 4) h o ur s after t h e e ve nt] t o t he Me dical 
M o nit or or desi g n ee at S oli ge ni x. 
Fi n di n gs fr o m t hese r e vie ws will be disc usse d wit h t he i n vesti gat or a n d staff. C o m plete d pa ges 
of t he e C R F  will be e v al uate d at eac h visit. T he d ates of t he m o nit ori n g visits will be rec or de d i n 
a si g n -i n l o g t hat will be ke pt at t he site. T he st u d y c o or di nat or a n d i n v esti gat or ar e e x pecte d t o 
be a vaila ble f or q uesti o ns, t he s o urce d o c u me ntati o n rea dil y a vaila bl e, a n d a s uita ble 
e n vir o n me nt pr o vi de d f or re vie w of st u d y- rel ate d  d oc u me nts. 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 6 0  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  1 2. 6. 5  Cl ose- o ut Visit  
T he cli nical res ear c h m o nit or(s) will perf or m a n e n d of trial visit t o e ns ure t hat:  
• All dr u g r ec o n ciliati o n f or ms are acc urate a n d c o m plete.  
• All u n use d st u d y dr u g is ret ur ne d t o t he a p pr o priat e l ocati o n. 
• All data iss ues are res ol v e d a n d e C R F are c o m plete d a n d verifie d.  
• T he I R B h as bee n n otifie d t hat t he st u d y has b ee n c o m plete d. 
• T he i n vesti gat or at eac h site is a ware t h at t he st u d y has bee n c o m plet e d a n d n o f urt her 
s u bjects are e nr olle d.  
1 2. 7.  A u dits a n d I ns pecti o ns  
Healt h A ut h orities (e. g., F D A, t he E M A, or c o u ntr y Healt h A ut h orities), i n t he pers o n of a 
trai ne d a n d pr o p erl y a ut h orize d e m pl o yee, ma y r e q uest access t o all st u d y r ec or ds, i ncl u di n g 
s o urce d oc u m e nts, f or i ns pecti o n a n d c o p yi n g. T h e i n vesti gat or will i m me diatel y n otif y 
S oli ge ni x of a n y u pc o mi n g i ns pecti o ns.  
Peri o dic a u diti n g i ns pecti o ns ma y als o be c o n d uct e d b y a re prese nt ati ve of t he Q ualit y 
Ass ura nce De p art me nt of S oli ge ni x or its trai ne d desi g nee(s).  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 6 1  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  1 3.  I N S TI T U TI O N A L R E VI E W  B O A R D (I R B)/ E T HI C A L 
C O M MI T T E E ( E C)  
All partici pati n g ce nters m ust ha ve i n place eit her a n I R B or t h e E C t hat meets all of t he criteria 
o utli ne d i n Secti o n 3 of t he I C H “ G ui da n ce f or I n d ustr y ; E 6 G o o d Cli nical Practice:  
C o ns oli date d G ui da nce”. C o pi[INVESTIGATOR_1309] t he I R B/ E C me m bers hi p list a n d pr oce d ures s h o ul d be 
pr o vi de d t o t he S oli ge ni x . 
It is t he r es p o nsi bilit y of t he site’s Pri nci pal I n vesti gat or ( PI) t o o btai n I R B/ E C writte n a p pr o val 
of t he pr ot oc ol, t he I nf or me d C o nse nt F or m, patie nt c o m pe nsati o ns details, a n d a n y 
a d vertise me nts t o be use d i n c o n d uct of t he trial. N o patie n t ca n b e e nr olle d i nt o t he trial pri or t o 
o btai ni n g t hese d o c u me nts. It is als o t he site’s PI r es p o nsi bilit y t o : 
Ass ure  t hat n o de viati o ns fr o m, or c ha n ges of, t he pr ot oc ol s h o ul d be i niti ate d wit h o ut pri or 
writte n I R B/ E C a p pr o v al/fa v ora ble o pi [INVESTIGATOR_9384] o n of a n a p pr o priate a me n d me nt, e x ce pt w he n 
necessar y t o eli mi nate i m me diate hazar ds t o t he s u bjects or w he n t he c ha n ge(s) i n v ol ves o nl y 
l o gistical or a d mi nistrati ve as pects of t h e trial (e. g., c h a n ge of m o nit or(s), tele p h o ne n u m ber(s))  
Pr o m ptl y re p ort t o t he I R B/ E C:  
o All d e viati o ns fr o m, or c ha n ges t o, t he pr ot oc ol t o eli mi nate i m me diate  hazar ds t o 
t he trial s u bjects  
o A n y c ha n ges i n creasi n g t he ris k t o s u bjects a n d/ or affecti n g si g nifica ntl y t h e 
c o n d uct of t he trial  
o All A Es  t hat are b ot h seri o us a n d u ne x pecte d  w het her see n at t hat i nstit uti o n or 
re p orte d fr o m S oli ge ni x  
o A n y n e w i nf or mati o n t hat ma y affect a d versel y t h e safet y of t h e s u bjects or  t he 
c o n d uct of t he trial. 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 6 2  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  1 4.  Q U A LI T Y C O N T R O L A N D Q U A LI T Y A S S U R A N C E  
It is t he r es p o nsi bilit y of t he PI [INVESTIGATOR_022]/ her desi g nee t o ass ure t hat all i nf or mati o n i n t he e C R F is 
acc ur ate a n d c o m plete. T he e C R F will perf or m i m me diate i nter nal c o nsiste nc y c hec ks t o 
mi ni mize p ote ntial f or err o ne o us data ( e. g., date of birt h after d ate of ra n d o mizati o n). S oli ge ni x 
will use m o nit ors t o re vie w e ntere d d ata i n t he e C R F a n d ma ke p eri o dic site visits t o c o m pare 
e C R F data wit h s o urce d oc u me nts. Peri o dic i nteri m a u dits fr o m S oli ge ni x’s Q ualit y D e part me nt 
or t heir desi g nee will be c o n d ucte d t o ass ur e t hat all I C H g ui deli nes are b ei n g f oll o we d a n d 
i de ntif y a n y s yste mic pr o ble ms wit h t he data or pr oce d ures.  Fi nal a u dits will be c o n d ucte d at 
re pres e ntati ve sites.  
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 6 3  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183486] be a p pr o v e d i n writi n g b y I R B / E C  bef ore e nr ol l me nt of a n y s u bject i nt o t he st u d y. 
T he PI [INVESTIGATOR_1660] t heir desi g nee is res p o nsi ble f or i nf or mi n g t he I R B / E C  of a n y S A Es  a n d a me n d me nt(s) 
t o t he pr ot oc ol as per re g ulat or y re q uire m e nts. 
[ADDRESS_1183487]’s si g ne d a n d d ate d i nf or m e d c o nse nt m ust be 
o bt ai ne d bef ore c o n d ucti n g a ny st u dy s pecific pr oce d ure . T he c o nse nt f or m t hat is use d m ust 
meet t he re q uir e me nts as o utli ne d i n t he I C H G ui d a nce o n G C Ps ( E 6) a n d m ust be a p pr o ve d b y 
b ot h t he re vie wi n g I R B / E C  a n d b y S oli ge ni x. 
[ADDRESS_1183488] ore d i n a 
c o m p uter data b ase, mai ntai ni n g c o nfi d e ntialit y . S u bjects i n t his data base will be i de ntifie d b y 
i nitials or e nr ol l me nt c o de/s u bject n u m ber o nl y. A n a ut h orize d re pres e ntati ve of a r e g ulat or y 
a ut h orit y ma y re q uire dir ect access t o parts of t h e trial site rec or ds rele va nt t o t he st u d y, 
i ncl u di n g s u bjects’ me di cal hist or y f or dat a verifi cati o n p ur p oses. 
1 5. 5.  Fi n a nci al Discl os ure  
T he F D A has iss ue d r e g ulati o ns ( 2 1 C F R Part 5 4) t hat re q uire S p o ns ors (i n t his case S oli ge ni x) 
t o s u b mit c o m plete a n d acc urat e certificati o n or discl os ure state me nts t o certif y t he a bse nce of 
certai n fi n a ncial i nter ests of cli nical i n vesti gat ors a n d/ or discl ose t h ose fi na ncial i nterests, as 
re q uire d, w h e n cli nical st u dies are s u b mitte d t o t he F D A i n s u p p ort of mar keti n g a p pr o val of a 
ne w dr u g a p plicati o n ( N D A). T hes e re g ulati o ns are i nte n de d t o e ns ur e t hat fi na ncial i nterests a n d 
arra n ge me nts of cli nical i n vesti gat ors, t hat c o ul d affect r elia bilit y of d ata s u b mitte d t o t he F D A 
i n s u p p ort of mar keti n g a p pr o val, ar e i de ntifie d a n d discl ose d b y t he S p o ns or. 
Re gar dless of t he l ocati o n of t he cli nical site, all cli nical i n vesti gat ors partici pati n g i n t his 
cli nical trial s hall be as ke d t o discl ose pr o prietar y (e. g., pate nt, lice nsi n g a gree me nt) a n d 
fi na ncial ( e. g., st oc k o pti o ns, r o yalt y) i nterests as t he y p ertai n t o S oli ge ni x, pri or t o partici pati n g 
i n t he st u d y. I n a d diti o n, cli nical i n vesti gat ors will be re q uir e d t o c o ns ult wit h S oli ge ni x bef ore 
ac q uiri n g a n y fi n a ncial i nterest i n t he c o m pa n y a n d m ust discl ose a n y c h a n ge i n t heir pr o p rietar y 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 6 4  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183489] u d y 
c o m pleti o n. Cli nical i n vesti gat or is defi n e d u n der Title 2 1 C F R Part 5 4 as a n i n vesti gat or or s u b- 
i n vesti gat or liste d o n t he F D A F or m 1 5 7 2 t hat is directl y i n v ol ve d i n t he tr eat me nt or e val uati o n 
of researc h s u bjects. T he re q uire me nt f or pr o pri etar y a n d fi na n cial discl os ur e als o i ncl u des a n y 
o w ners hi p b y t he s p o use or a n y de pe n d e nt c hil d of t he i n vesti gat or. 
If t he F D A deter mi nes t hat t he fi na ncial i n ter ests of a n y cli nical i n vesti gat or raise seri o us 
q uesti o ns a b o ut t he i nte grit y of t he d ata, t he F D A will ta ke a n y acti o n it dee ms necessar y t o 
e ns ure t he r elia bilit y  of t he data, i ncl u di n g: 
I nitiati n g a ge n c y a u dits of t he data deri ve d fr o m t he cli nical i n vesti gat or i n q uesti o n; 
Re q uesti n g t hat t he S p o ns or s u b mit f urt her a nal ys es of data, e. g., t o e val uat e t he effect of t h e 
cli nical i n vesti gat or’s dat a o n o verall st u d y o utc o me;  
Re q uesti n g t hat t he a p plica nt c o n d uct a d diti o nal i n de pe n de nt st u dies t o c o nfir m t he res ults of t he 
q uesti o ne d st u d y; a n d/ or 
Ref usi n g t o treat t he c o v ere d cli nical st u d y as pr o vi di n g data t hat ca n be t h e basis f or a n a ge n c y 
acti o n.  
If t he S p o ns or d oes n ot i ncl u de certificati o n or discl os ure, or b ot h, if r e q uire d, or d oes n ot certif y 
t hat it was n ot p ossi ble t o o btai n t he i nf or mati o n, t he F D A m a y ref use t o fil e t he N D A . 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 6 5  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: 1 7  S e pt e m b er 2 0 1 9  1 6.  D A T A H A N D LI N G A N D R E C O R D K E E PI N G  
1 6. 1.  I ns pecti o n of Rec or ds  
As n ote d i n Secti o n 1 3. 6, it is t he res p o nsi bilit y of t he PI a n d t he partici p ati n g i nstit uti o n t o 
ass ure t hat a p pr o priate tri al -relat e d m o nit ori n g, a u dits, I R B/ E C re vi e w, a n d re g ulat or y 
i ns pecti o n(s) ca n b e carri e d o ut b y ass uri n g direct access t o s o urce d ata/ d oc u me nts. T hese 
i ns pecti o ns ma y b e c o n d ucte d b y S oli ge ni x  or its desi g nee or r e pr ese ntati v es of t he F D A, E M A, 
or l ocal Healt h A ge ncies.  
[ADDRESS_1183490] a p pr o val of a 
mar keti n g a p plicati o n i n a n I C H re gi o n a n d u ntil t here are n o p e n di n g or c o nte m plate d mar keti n g 
a p plicati o ns i n a n I C H re gi o n; at least [ADDRESS_1183491]; or 7 years si nce t h e cl ose -o ut of t he cli nical 
trial . S oli ge ni x  will i nf or m t he i n vesti gat or /i nstit uti o n as t o w he n t hese d oc u me nts n o l o n ger 
nee d t o be r etai ne d . 
If t he res p o nsi ble i n vesti gat or retires, rel ocates, or f or ot her r eas o n wit h dr a ws fr o m t he 
res p o nsi bilit y of kee pi n g t he st u d y r ec or ds, c ust o d y m ust be tra nsferre d t o a pers o n w h o will 
acce pt t he res p o nsi bilit y. S oli ge ni x m ust be n otifie d i n writi n g a n d a p pr o ve of t he na me a n d 
a d dress of t he n e w c ust o dia n. 
[ADDRESS_1183492] u d y’s PI , t he [ADDRESS_1183493] u d y statisti cia n, a n d r e pr ese ntati ves of S oli ge ni x . 
Ot her me m bers ma y b e a p p oi nte d at t he i nitial P u blicati o n C o m mittee meeti n g.  
 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
 Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 6 6  of 6 7  
A m e n d m e nt 1: 2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183494] it uti o nal Re vie w B oar d/ Et hics 
C o m mittee a n d S oli ge ni x a n d will f ulfill all res p o nsi bilities f or s u b mitti n g perti ne nt i nf or mati o n 
t o t he I nstit uti o nal Re vie w B oar d/ Et hics C o m mittee res p o nsi ble f or t his st u d y.  
I f urt her a gree t hat t he H ealt h A ut h orities, S ol i ge ni x, or t heir desi g nee(s) s hall ha ve access t o a n y 
s o urce d oc u m e nt fr o m w hic h case re p ort f or m i nf or mati o n ma y h a ve bee n ge n erat e d. 
I a gree t hat I a n d all i n vesti gat ors liste d o n t he F D A F or m [ADDRESS_1183495] u d y’s c o m pleti o n. 
 
 
 
   
I n v esti gat or's Si g nat ure  Date  
 
 
  
Na me of I n v esti gat or ( T y pe d or Pri nte d) 
 
 
 
 
 
 
Pr ot o c ol I D R -O M -0 2 -U S A     
 
Ori gi n al: 1 1 J a n u ar y 2 0 1 7  C o nfi de nti a l P a g e 6 7  of 6 7  
A m e n d m e nt 1:  2 9 N o v e m b er 2 0 1 7   
A m e n d m e nt 2: 2 2 J a n u ar y 2 0 1 8  
A m e n d m e nt 3: [ADDRESS_1183496] os o me- 1/ p 6 2 is t he key i ntr acell ul ar t ar get of i n n ate defe nse 
re g ul at or pe pti de.  J Bi ol C he m, 2 0 0 9. 2 8 4 ( 5 2): p. [ADDRESS_1183497] a nt i nfecti o ns: 
I n n ate Defe ns e Re g ul at ors as a n a g n ostic t her a py.  J Bi otec h n ol o g y, 2 0 1 6. 2 2 6 : p. [ADDRESS_1183498] ace b o- C o ntr olle d P h ase 2 a Cli nic al a n d 
Precli nic al D at a De m o nstr ati n g a Si g nific a nt a n d C o nsiste nt Re d ucti o n i n D ur ati o n of 
Or al M uc ositis wit h a N ovel I n n ate D efe nse R e g ul at or.  J Bi otec h n ol o g y, 2 0 1 6. 2 3 9 : p. 
1 1 5- 1 2 5. 
4.  Sc ott, M. G., et al., A n a nti- i nfective pe pti de t h at selectively m o d ul ates t he i n n ate 
i m m u ne res p o nse.  N at Bi otec h n ol, 2 0 0 7. 2 5 ( 4): p. [ADDRESS_1183499] u g C a n di d ate.  Bl o o d, 2 0 1 0. 
1 1 6 ( A S H A n n ual Meeti n g A bstr acts): p. 3 7 8 1. 
6.  W H O, W. H. O., W H O H a n d b o ok f or re p orti n g res ults of c a ncer tre at me nt.  1 9 7 9, 
Ge ne va.  
7.  S o nis, S. T., Ne w t h o u g hts o n t he i niti ati o n of m uc ositis.  Oral Dis, 2 0 1 0. 1 6 ( 7): p. 5 9 7- 
6 0 0. 
8.  Me hta, C. R. a n d S.J. P oc oc k, A d a ptive i ncre as e i n s a m ple size w he n i nte ri m res ults are 
pr o misi n g: a pr actic al g ui de wit h ex a m ples.  Stat Me d, 2 0 1 1. 3 0 ( 2 8): p. 3 2 6 7- 8 4. 
 